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Abstract 
Aligning Acute and Chronic Functional Readouts and Utilizing Zolpidem to Improve 
Neurological Impairments After Cardiac Arrest  
 
David Fine, MS 
 
University of Pittsburgh, 2020 
 
 
 
 
While cardiac arrest survival rates have improved alongside recent advances in modern 
resuscitation techniques and targeted temperature management, many survivors experience 
multiple ongoing symptoms after their hypoxic-ischemic brain injury (HIBI) including movement 
disorders, depression, and low cognitive arousal.  Neurological assessments like the neurological 
deficit score (NDS), and physiological readouts from blood chemistry values are used to assess 
acute post-injury outcome, but little has been done to evaluate how these acute readouts distinguish 
heterogeneity within the injury population, or how they align with long term behavioral and 
neurological outcomes as a prognostic tool. Recent evidence also highlights zolpidem as an 
effective treatment for post-HIBI symptoms, but its clinical use has been met with mixed results.  
This study utilized a regression model and correlational analyses to evaluate associations among 
NDS, blood lactate, and blood acid base excess values as acute post-injury readouts, behavioral 
outcome, and dopamine neurotransmission outcomes obtained via fast scan cyclic voltammetry 
two weeks after a 5-min asphyxia cardiac arrest (ACA).  A pilot study was also performed to 
evaluate the effects of chronic systemic zolpidem administration on improving behavioral 
outcomes and reversing striatal hyper-dopaminergia after ACA.  NDS significantly aligned with 
survival probability after ACA.  NDS and both blood chemistry readouts aligned with several 
behavioral and dopamine neurotransmission outcomes, and several dopaminergic and behavioral 
outcomes robustly correlated with one another.  Additionally, chronic zolpidem reflexive and 
 v 
cognitive behavioral outcomes, as defined by the acoustic startle response and the sucrose 
preference test, respectively.  This work highlights novel associations between post-HIBI 
behavioral and neurological outcomes as well as benefits of chronic zolpidem administration in 
ameliorating post-HIBI neurological sequelae.  Future work should further characterize the effects 
of zolpidem administration after cardiac arrest and utilize molecular assays to identify protein 
expression changes that will unravel neurobiological mechanisms driving HIBI-induced functional 
impairments and highlight therapeutic targets to treat CA survivors. 
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1.0 Introduction 
The annual incidence of out-of-hospital cardiac arrest (CA) in the U.S. is approximately 
360,000 cases per year1.  While CA survival rates have improved alongside recent advances in 
modern resuscitation techniques and targeted temperature management, prevalence of good 
functional outcomes after neurorehabilitation is as low as 6%2,3, leaving many individuals with 
multiple ongoing symptoms.  In addition to disorders of consciousness (DoC), anxiety/depression, 
agitation/restlessness, and low cognitive arousal, the hypoxic-ischemic brain injury (HIBI) 
resulting from CA afflicts survivors with a variety of movement disorders ranging from abnormal, 
involuntary movements and seizure to more parkinsonian symptoms like dystonia, chorea, and 
tremor4.  Though these symptoms overlap with other neurological disorders, many of which 
involve striatal dopamine (DA) dysfunction, CA survivors represent a “new” clinical population, 
and little work has been done to develop effective treatments to combat CA pathology. 
CA survivors share many cognitive features with individuals who have suffered a 
significant traumatic brain injury (TBI), and current clinical practice for HIBI treatment borrows 
approaches used with other brain injury populations.  However, the pathologies underlying HIBI 
and TBI symptoms may differ greatly depending on injury etiology.  Experimental TBI studies 
suggest a state of striatal hypodopaminergia or suppressed DA neurotransmission following the 
injury, prompting the use of DA agonists like methylphenidate to improve symptoms 
accompanying the injury5.  Using a rodent model of ventricular fibrillation cardiac arrest (VF-CA) 
paired with fast scan cyclic voltammetry (FSCV) to conduct in vivo, real time characterization of 
presynaptic DA, our research team discovered abnormally elevated DA neurotransmission two 
weeks following the injury, which is worsened by methylphenidate administration6.   
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The cause of CA also influences both the duration of ischemia and the cerebral blood flow 
changes during brain reperfusion, two key factors that determine the injury outcome7.  Asphyxia 
cardiac arrest (ACA) arises from respiratory failure, as seen with intoxication, drowning, or 
trauma, and causes more severe morphologic brain damage than VF-CA8.  ACA also exhibits 
different brain reperfusion characteristics than VF-CA which affect more brain regions – ACA-
induced hyper-perfusion of both the cortex and thalamus whereas VF-CA only leads to early 
hyperperfusion of the cortex7.    
Additionally, ACA is a dynamic injury impacted by many variables in clinical settings and 
in experimental models.  For example, the ischemic brain is sensitive to temperature such that 
small differences in ambient temperature critically influence neuropathological outcomes in brain 
regions responsible for motor behavior and cognition 9,10.  Insult severity also varies within the 
same injury model and even within the same breed of rat (Sprague-Dawley) across multiple 
vendors11. 
Neurological assessments are often used to assess acute post-injury outcome.  Neurological 
deficit scores (NDS) have been utilized to evaluate the effects of hypothermia12, as well as the 
differential effects of sodium bicarbonate and epinephrine dosages on initial recovery13 from CA 
which has aided resuscitation management advancements. Physiological assessments such as 
blood chemistry readings are also utilized to assess post-injury outcome.  Blood lactate levels, for 
example, strongly correlate with mortality after CA which contribute to early patient prognosis14.  
However, research exploring associations between physiological readouts and functional 
outcomes is lacking in several areas.  For example, most studies focus on acute timepoints rather 
than more long-term outcomes.  With regard to experimental ischemic injury models, little work 
has been done in utilizing these readouts to 1) identify heterogeneity within individual injury 
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models, and 2) evaluate how these readouts align with, and influence behavioral outcomes. HIBI 
symptomologies implicate striatal DA dysfunction and elevated striatal DA levels have been 
reported following VF-CA 6 and ACA, the latter of which has been shown to induce deficits in 
reflexive, exploratory, and cognitive behavior (Not yet published).  As such, exploring associations 
between acute physiological readouts and DA neurotransmission outcomes may offer mechanistic 
insight to post-HIBI neurological sequelae and highlight potential therapeutic targets. 
HIBI affects certain brain regions more than others, with damage localized to the brain’s 
vascular watershed and metabolically demanding neuronal subtypes within the hippocampus, 
thalamus, cerebellum, and cortex15,16.  Striatal medium spiny neurons (MSNs) are also particularly 
vulnerable to ischemic damage17,18and exhibit early, irreversible damage from ischemia19.  These 
GABAergic neurons make up 80-90% of the striatal population and receive dense DAergic input 
from the substantia nigra pars compacta (SNpc).  Also, through their modulation of cortical 
glutamatergic input and aspiny acetylcholine (ACh) interneurons, MSNs play key roles in 
cognition, behavior, motivation, and controlled movement.  MSNs receive MSNs with type 2 DA 
receptors (D2Rs), which are associated with dystonia, chorea, and cognitive disorders20–24 are 
particularly vulnerable to Huntington’s Disease-like metabolic dysfunction/damage25,26.   
Evidence also shows uncontrolled striatal DA release seen after even a mild hypoxic-ischemic 
insult which is more severe than ischemia‐induced increases of other neurotransmitters27,28.  As 
aberrant DA signaling underlies movement disorders in Parkinson’s disease (PD) and HD29, DA 
neurotransmission changes after CA may facilitate HIBI-induced motor abnormalities.  The 
thalamic reticular nucleus (tRN) is also particularly vulnerable to ischemic injury.  Another 
primarily GABAergic region, the tRN provides inhibitory modulation of the intralaminar (iLN) 
thalamus, a crucial component of the reticular activating system (RAS) which, through its 
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communication with the cortex, regulates conscious states.  HIBI-induced neuronal damage in the 
tRN likely facilitates abnormal thalamocortical signaling that drives DoC after CA. 
Further, disinhibited DA release and imbalance of other DA neurotransmission elements 
like ACh may also lead to cognitive disorders that impair function after CA30–32.  Figure 1 depicts 
the relevant neurotransmitter pathways involved in striatal circuitry that support coordinated 
movement, arousal, and consciousness as well as the consequences of HIBI on their functionality.   
 
 
Figure 1:  Graphical depiction of neurotransmitter pathways feeding involved in polysynaptic intrastriatal 
circuitry that support coordinated movement and also arousal and consciousness (Davis/Wagner 2019). 
(A) Uninjured Circuit: DAergic projections from the SNpc provide excitatory input into D1 MSNs and 
inhibitory input into D2 MSNs.  DAergic stimulation of MSNs is modulated by cholinergic input from aspiny 
neurons and from glutamatergic cortico-striatal afferents. M4 activation on D1 MSNs blunt MSN output 
while M1 activation on both D1 and D2 MSNs provides an excitatory effect; generalized muscarinic 
stimulation leads to D1 MSN inhibition, and D2 MSN activation modulates the impacts of DA and glutamate 
on GABAergic MSN pallidal-thalamic relays and nigral projections. (B) Injured Circuit: HIBI results in 
damage/loss of metabolically vulnerable MSNs.  Reduced GABAergic pallidal outflow by HIBI reduces GPi 
inhibitory output to thalamus, facilitates excitotoxicity from subthalamic nucleus projections, causes delayed 
damage to GABAergic neurons in SNpr that may facilitate hyperdopaminergia observed in our ACA model.   
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Elevated DA levels post-HIBI may excessively inhibit tonically active aspiny Ach neurons that then promotes 
overactivation of remaining D1 MSNs and overinhibition of remaining D2 MSNs.  
Legend: MSN, Medium Spiny Neuron; HIBI, hypoxic ischemic brain injury; SNpr, Substantia nigra pars 
reticulata; DA, Dopamine; Ach, acetylcholine. (Green—excitatory effects on post-synaptic neuronal firing, 
red—inhibitory on post-synaptic neuronal firing. Bolded colors represent augmented neurotransimission 
effects due to HIBI. Grey—dying/dysfunctional MSNs. 
 
Striatal MSNs project topographically to the internal and external globus pallidus (GPi and 
GPe, respectively) as part of the “direct” and “indirect” pathways of movement, as well as to the 
substantia nigra pars reticulata (SNpr) and SNpc.  Striatal DA release by dopaminergic SNpc 
projections are regulated in part by direct and indirect GABAergic feedback from MSNs33–35 and 
this GABAergic control of the SNpc strongly influences its firing properties34. GABAergic 
afferents from the GPe also strongly influence the firing properties of both nigral regions34,36,37. 
MSNs and GABAergic interneurons also provide inhibitory feedback to spiny ACh interneurons 
and with each other, creating complex intra-striatal networks and functional units that influence 
the larger striatal-pallidal-thalamic circuitry underlying coordinated movement and consciousness.  
Given these ideas, disrupted GABAergic outflow resulting from MSN damage and dysfunction 
may facilitate striatal hyperdopaminergia and abnormal thalamocortical transmission that 
manifests itself as movement and hypoarousal disorders.  Given the specific vulnerability of 
striatal MSNs to ischemia, this evidence suggests that altering GP-mediated GABAergic feedback 
to the SNpc may reverse striatal hyperdopaminergia after HIBI and ameliorate movement 
disorders and DoC.   
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Figure 2: Uninjured striatal-pallidal-nigral circuit (A) and HIBI-affected striatal-pallidal-nigral circuit (B). 
(B) Hypoxic ischemic brain injury (HIBI) leads to acute striatal neuron dysfunction with selective D2 MSN 
vulnerability.  The resulting increase in pallidal (GP) outflow inhibits GABAergic SNpr neurons and 
indirectly dis-inhibiting SNpc DAergic neurons, thus leading to elevated striatal DA levels. 
 
Depression is a major symptom observed after both traumatic and ischemic brain injury, 
with roughly 40% of stroke patients suffering from post-stroke depression (PDSD)38,39.  Though 
anhedonia, the reduced ability to experience pleasure, is relatively easy to identify using animal 
models, its neurobiological underpinnings are not well understood.  As dopaminergic signaling 
plays a key role in pleasurable experiences, with mesolimbic dopaminergic neurons encoding the 
information eliciting motivational value and motivational salience40–42, normalizing HIBI-induced 
DA neurotransmission aberrations may ameliorate depression symptoms following ACA.  
Inflammation likely influences post-HIBI behavioral abnormalities as well.  The inflammatory 
response to systemic infections influences central nervous system changes that facilitate symptoms 
referred to as sickness behaviors.  Through its effects on DA signaling, inflammation has been 
shown to affect basal ganglia-relevant behaviors such as motivation and motor activity43–45.  
Elevated microglial activation and striatal tumor necrosis factor alpha (TNFa) after VF-CA46 
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suggest that ongoing neuroinflammation may also contribute to post-HIBI behavioral 
abnormalities. 
The acoustic startle response (ASR) also plays an important role in neuropsychiatric 
disease studies because its disruption often indicates broader neurological problems. It 
demonstrates a phenomenon called pre-pulse inhibition (PPI), a type of stimulus desensitization 
affected in several neurological disorders associated with DA signaling abnormalities.  TBI, which 
is shown to suppress DA neurotransmission, induces a long-lasting suppression of the ASR as 
well47.  Schizophrenia and HD, disorders associated with hyperactive DA,  provoke an amplified 
ASR as well as PPI deficits48–50. The ASR is mediated by a tri-synaptic pathway in the lower 
brainstem and spinal cord and is depicted in Figure 3.  Auditory information is translated into 
neural signals at the cochlear nuclei.  The cochlear nuclei then relay these signals via the 8th cranial 
nerve to the pontine reticular nucleus (PnC) whose projections innervate hundreds of motor 
neurons, via the reticulospinal tract in the medial longitudinal fasciculus of the spinal cord, in 
response to the stimulus51,52.  
 
Figure 3: Schematic representation of acoustic startle response circuit. 
 
 The pontine reticular formation (pRF), particularly its caudal nucleus, The pRF acts as a 
sensorimotor interface where the transition of sensory input into motor output can be directly 
influenced by excitatory or inhibitory afferents, thus playing an important role in mediating the 
ASR53.  
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The basal ganglia also provide the exploratory drive needed for navigation, foraging, and 
other reward-based or reinforcement learning54, though little is known regarding the 
neurobiological mechanisms of exploratory behavior.  Seminal work from O’Keefe and Nadel 
highlighted the relationship between exploration and spatial memory, a largely hippocampus-
dependent function55.  Experimental models of middle cerebral artery occlusion (focal ischemic 
stroke) suggest the injury causes exploratory hyperactivity56,57, which aligns with the role of spatial 
memory in exploration and the vulnerability of hippocampal neurons to ischemic injury.  Without 
habituation facilitated by the hippocampus, animals may feel compelled to increase exploration, 
leading to duplication of exploration efforts for example.  However, this behavioral abnormality 
hasn’t been explored in the context of CA-associated HIBI, and behavioral responses to ischemia 
are influenced by other external factors such as lighting58 and time after the injury59.   
Recent evidence highlights zolpidem, otherwise known as Ambien, as an effective therapy 
to treat post-HIBI symptoms.  Commonly used as a hypnotic/sedative agent, zolpidem is a GABAA 
receptor agonist with a high selectivity for those expressing the 1 subunit.  The distribution of 
these receptors throughout the basal ganglia allow them to exert a direct influence on striatal DA 
neurotransmission and thalamocortical signaling.  Under normal conditions, zolpidem induces 
hypnotic effects by suppressing thalamocortical signaling via its action on tRN GABAA-1-
receptors.  However, paradoxical effects on arousal after zolpidem administration have been 
described in clinical case studies of severe trauma60,61 and CA-induced HIBI62–65.  It’s 
administration has also been linked to improvement in Parkinson’s associated movement 
disorders66,67.   
Though it’s mechanism is largely theoretical68, systemic zolpidem may ameliorate HIBI-
associated behavioral impairments by partially replacing the function of striatal MSNs (i.e. 
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GABAergic striatal outflow).  GABAA- α-1 receptors are expressed in the striatum, GP, SNpr, and 
the tRN69.  As such, systemic zolpidem administration may normalize striatal outflow and thus GP 
outflow as well.  As increased pallidal outflow after HIBI disinhibits SNpc DAergic neurons and 
drives post-CA striatal hyperdopaminergia, normalizing the neuronal firing of the striatal-pallidal 
circuitry may normalize SNpc DAergic neurons and reverse striatal hyperdopaminergia, as seen 
in figure 4.  Though HIBI results in amplified GPi inhibitory drive which would presumably 
suppress thalamocortical signaling, animal models show elevated thalamocortical neuronal firing 
after CA70,71.  Zolpidem’s actions on the high concentration of GABAA- α-1 receptors in the tRN 
may normalize inhibitory drive on the intralaminar thalamus and ameliorate post-HIBI DoC.   
 
Figure 4: Mechanistic theory of HIBI-affected striatal-pallidal-nigral circuitry before (A) and after (B) 
systemic zolpidem administration. 
(B) Systemic zolpidem administration may normalize striatal GABAergic outflow by acting on striatal 
GABAA- α-1 receptors.  Increased MSN outflow to the SNpc and GP may directly and indirectly increase 
inhibitory drive onto SNpc DAergic neurons, thus reversing striatal hyperdopaminergia. 
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Zolpidem treatment, however, has highly mixed results within the clinical population72–
76. Given the broad and heterogeneous distribution of GABAA- α-1 receptors.  The neurological 
changes underlying post-HIBI symptoms are dynamic processes as well.  Taken with the idea that 
these regions interact within various closed loop circuits and influence a variety of basal ganglia-
driven behaviors, zolpidem may exert vastly different downstream effects depending on where it 
binds its receptor. 
This thesis aimed to elucidate the value of acute neurological and physiological readouts, 
as defined by neurological deficit scores, blood lactate values, and blood acid/base excess (ABE) 
values, in identifying heterogeneity among a population of animals which underwent a 5-min ACA 
injury model.  The degree to which these acute readouts aligned with long-term behavioral, as well 
as neurological outcomes as indicated by DA neurotransmission findings from FSCV, was also 
evaluated.   
Subsequently, the effects of chronic, systemic zolpidem administration on normalizing DA 
kinetics and behavioral abnormalities were assessed in comparison to untreated ACA animals.  It 
was hypothesized that chronic zolpidem administration would ameliorate HIBI—induced 
behavioral deficits and reverse striatal hyperdopaminergia after ACA. Further, a cohesive 
conceptual framework, methodology, and technical feasibility plan was developed to test the 
impacts of regional zolpidem microinjections in the GPe, a key area in the regulation of controlled 
movement and consciousness that has dense expression of GABAA- α-1 receptors.   
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2.0 Methods 
Asphyxial Cardiac Arrest Model 
Rats (n=56) were randomly selected to undergo the 5-min ACA model or sham procedure.  
Rats were housed in pairs prior to surgical procedures and were allowed unrestricted access to 
food and water as well as a 12-hr light/dark cycle, then were housed alone following recovery from 
the surgery.  Those assigned to the ACA or sham group underwent procedures as described 
previously7.  In brief, adult male Sprague-Dawley rats (350-400g; Envigo, Frederick, MD, USA) 
were housed for at least 3 days before the experiment under 12-h light/dark cycle with unrestricted 
access to food and water. On the day of the experiment, rats were anesthetized with isoflurane 4% 
in inspiration fraction of Oxygen (FiO2), intubated with a 14 gauge intravenous catheter (Becton 
Dickinson, Sandy, UT, USA) and mechanically ventilated (Harvard Rodent Ventilator 683, 
Harvard Apparatus, South Natick, MA, USA; tidal volume 6 ml/kg, initial respiratory rate 40/min, 
positive end-expiratory pressure 5 cm H2O FiO2 0.5), while held at euthermia by an overhead lamp 
and heating pad. Anesthesia was maintained with isoflurane 2%. Left femoral artery and vein were 
cannulated with polyethylene (PE) tubing (PE60 and PE90, respectively, Masterflex, Barnant, IL, 
USA) for blood pressure monitoring and drug administration, respectively, via surgical cutdowns. 
Baseline arterial blood gas (ABG) was obtained to assess acid-base balance and hematologic 
parameters with glucose and lactate. 
Rats assigned to the ACA group received the following additional treatment: After 5-
minute ACA induced by disconnection from the ventilator, epinephrine (50 µg/kg) and bicarbonate 
(1 mmol/kg) were given intravenously at the start of CPR. Additional epinephrine (25 µg/kg) was 
given 60s after the start of CPR. Resuscitation was performed via mechanical ventilation (FiO2 
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1.0, identical respiratory parameters as above) and manual chest compression (300/min) until 
return of spontaneous circulation (ROSC). If ROSC was not achieved within 2 min of CPR, rats 
were defibrillated (Zoll 3M, Chelmsford, MA, USA; 10 J biphasic shock between sternal and 
esophageal electrode positioned behind the heart); defibrillation attempts were repeated if needed 
every 30 s during ongoing CPR. Sham rats received all surgical procedures except those directly 
associated with ACA and resuscitation under isoflurane anesthesia (1% with FiO2 identical to the 
corresponding stage of the ACA protocol).  
Post-Resuscitation Care 
Arterial blood gases were obtained at 5-min post-ROSC, 30-min (prior to weaning from 
the ventilator) and 60-min (after weaning from the ventilator) post-ROSC. Rats were weaned from 
the ventilator at 30-min after ROSC, allowed to breathe spontaneously via endotracheal tube with 
supplemental oxygen delivered via nose-cone mask at 2L/min. Using a midline laparotomy 
incision, a Mini-Mitter probe (Mini-Mitter Co., Sunriver, OR, USA) was inserted into the 
peritoneal cavity to allow post-operative temperature control and continuous monitoring of vital 
functions. Rats were extubated 60 min after ROSC following decannulation. Then, rats were 
placed in cages and kept normothermic using an overhead heating lamp and/or a fan for 18 h in 
addition to supplemental oxygen (2L/min for 18 h) and unlimited access to food and water. The 
Mini-Mitter probe was removed 24 h later under brief isoflurane anesthesia using a nose-cone 
mask. Rats were then moved to the housing facility with a 12 h dark/light cycle, and unlimited 
access to standard food and water. Rats were housed individually in a standard environment. 
Neurological function was assessed daily for the first 3 days using an Overall Performance 
Category (OPC) score (1 = normal - ambulating, eating, drinking; 2 = mild disability - as OPC 1 
but with abnormal sensory or motor function; 3 = moderate disability - responds to pain, no 
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ambulation, no righting, no eating or drinking, conscious; 4 = severe disability - no ambulation, 
no righting, no eating or drinking, comatose; 5 = death)77 and a modified Neurologic Deficit Score 
(NDC; 0 - 10% = normal, 100% = maximum deficit)78,79. 
Acoustic Startle Response (ASR) 
To assess HIBI-induced changes in the acoustic startle response and pre-pulse inhibition 
(PPI), ASR was performed one day before, as well as 3 days post-ACA or sham surgery. Each rat 
was placed in a Panlab Startle and Fear Conditioning Chamber using Packwin V.2.0 software and 
exposed to pseudorandomized intertrial 15 - 35 second white noise bursts at 85 dB, 95 dB, and 
105 dB occurring over approximately 15 minutes following a 10 minute period of habituation 
(Harvard Apparatus, Holliston, MA, USA). 8 bursts occurred at each volume for a total of 24 
bursts. The mean of maximum startle response amplitude (%) was calculated as a percentage for 
each of the three volume noise bursts. The percent (%) change of startle response of baseline 
compared to day 3 post-ACA or sham surgery. 
Myoclonus Testing 
Myoclonus testing occurred on D2 post-ACA or sham surgery. Rats were placed in a black 
receptacle (16” x 10” x 24”) and were exposed to metronome (Korg, Tokyo, Japan) clicks at 95 
dB volume over 60 seconds at a frequency of 45 beats per minute or 45 total clicks through an 
amplifier (Peavy, Meridian, MS, USA) located directly adjacent to the testing container following 
a 10 min habituation period in the black receptacle. Experiments were recorded using a digital 
video camera (Canon, Huntington, NY, USA). Graders blinded to the treatment group later 
watched the videos at reduced speed and assigned a categorical score for each of the 45 clicks: 1 
= no reaction, 2 = startle reaction, 3 = Myoclonic reaction, 4 = stereotypy reaction. The average 
number of myoclonic responses for each treatment group were calculated. 
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Open Field Testing 
Open field testing (OFT) was performed 7 days post-ACA or sham procedure. Following 
a 30 minute period of habituation in the testing room, rats were placed at the center of the open 
field apparatus (36.5”x 36.5” x 16”) facing the back wall and tracked using ANYMAZE software 
(Stoelting, Wood Dale, IL, USA) for the entire 600 seconds of the test. The measurements recorded 
included the total distance travelled (m), exploratory zone time allocation (%), and peripheral zone 
time allocation (%). 
Sucrose Preference Testing (SPT) 
Beginning 3 days post-ACA or sham procedure, rats were habituated with one bottle of 1% 
sucrose solution and one identical bottle of normal water. The position of these bottles (left or 
right) was switched until day 6, when two bottles of normal water were presented. On day 7 at 
3:00 PM, rats were deprived of all fluid for 18 hours. At 8:00 AM the following day, 100 mL of 
tap water and 1% sucrose water were presented to rats for 1 hr in a quiet location. Consumption 
was measured at the end of the experiment and preference for sucrose water (%) was calculated 
by dividing the volume of sucrose water consumed by the total volume of water consumed. 
Fast Scan Cyclic Voltammetry 
Two weeks following ACA / Sham procedures, rats underwent fast scan cyclic 
voltammetry to measure regional variations of DA neurotransmission as described previously.5 In 
brief, rats were anesthetized with urethane (1.3 g/kg), mounted onto a stereotaxic apparatus and 
maintained at 37℃ with a homeothermic blanket (Harvard Apparatus, Holliston, MA, USA). 
Midline incisions were made and soft tissues lifted to expose the skull to drill burr holes for the 
placement of microelectrodes. Carbon fiber microelectrodes (CFE) were fabricated as described 
previously.80 Immediately prior to use, electrodes were electrically pretreated with a 70 Hz 
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biphasic cyclic waveform (0V→2V→0V) to enhance DA sensitivity. One recording 
microelectrode was inserted using flat skull coordinates (in mm) into the dorsal striatum [anterior 
posterior (AP): +1.0, mediolateral (ML): +3.0, and dorsoventral (DV): -4.6]81. A reference 
electrode was placed on the proximally exposed brain tissue to create a salt bridge. A bipolar 
stimulating electrode (MS301-1; Plastics One, Roanoke, VA, USA) was inserted into the median 
forebrain bundle (AP: -4.3, ML: +1.6, DV: -6.6)81. 
Biphasic 60 Hz, 5 s (280 μA amplitude and 2 ms pulse width) stimulations of the median 
forebrain bundle were used to evoke DA overflow. DA responses were electrochemically detected 
by the CFEs to which a triphasic cyclic voltage waveform (0V>1V>0.5V>0V) was applied at a 
rate of 400 V/s every 100 ms, using TarHeel CV software (ESA, Chelmsford, MA, USA). The 
stimulating electrode was advanced 200μm every 5 min until a DA signal was detected and then 
lowered 100μm every 10 min until a peak signal amplitude was obtained in the CFE. Experimental 
DA responses were then obtained using alternating 60- and 40 Hz stimulations for 2, 5 or 10 
seconds according to the schematic depicted in Figure 1.  
 
         
Figure 5: Schematic outlining FSCV experimental design and median forebrain bundle stimulation sequence. 
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Following in vivo electrode measurements, electrodes were calibrated with seven DA 
concentrations in artificial cerebrospinal fluid (pH = 7.2) composed of (in mM): 1.2 CaCl2, 2.0 
Na2HPO4, 1.0 MgCl2, 2.7 KCl, and 145 NaCl80. The DA concentration versus current calibration 
using a quadratic regression, which was then used to convert experimental DA responses from 
measured currents to DA concentrations. 
Interpretation of DA Responses 
DA response shapes were assessed by evaluating peak DA concentrations associated with 
experimental DA response amplitudes, or evoked overflow (EO) [DA]. 
As validated and used in previous studies, we implemented the quantitative neurobiological 
(QN) framework to model kinetic parameters onto DA responses to 60 Hz, 10 and 5 s stimulations 
obtained from ACA and Sham rats.80  The QN framework was used for characterizing DA release 
and reuptake in lieu of the classic Michaelis-Menten (M-M) model82 because it does not assume 
constant DA release rate or a constant reuptake efficiency and affinity for DA on the part of DAT. 
The equations and terms used in the QN model to describe release and reuptake components of 
stimulated DA responses can be found in Table 1. Briefly, DA release rate during stimulation 
(DARstim) is described by equation 1 as an exponential decay function with a time constant of 
ΔDARτ and a steady-state release rate (DARSS). Post-stimulation DA release rate (DARpost) is 
described in equation 2 as release rate that decreases biphasically after stimulation ends, with a 
rapid exponential and prolonged linear decay components. Lastly, reuptake kinetics were modeled 
similarly to the M-M model, except Km was defined as a dynamic term that increases during 
stimulation according to the logistic function in equation 3 to model a decreasing reuptake 
efficiency caused by the stimulation itself. 
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Table 1: Equations and parameters utilized in stimulations. 
 
The simulations produced estimates of DA release and reuptake rates over the time course 
of stimulated DA responses. Specifically, we examined four parameters that were derived from 
these simulations to characterize the effects of ACA on stimulated DA neurotransmission: Kmi, 
Vmax, initial DA release rate (DARi), and DA released. Kmi describes the M-M constant that 
estimates the efficiency of DAT molecules at physiological conditions, and Vmax is an estimate of 
maximum reuptake rate that depends upon local DAT density and efficiency. As DA release is a 
dynamic process during stimulation, we provided estimates of DARi and total estimated DA 
released during stimulation by integrating DA release rate equations over the stimulation duration. 
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Zolpidem Administration 
Zolpidem was dissolved in DMSO, vortexed until fully dissolved, and then dissolved into 
0.1M PBS to bring the solution to 20% total DMSO.  Animals received daily intraperitoneal 
injections of either 0.1mg/kg (n=5) or 0.2mg/kg (n=5) zolpidem solution were performed starting 
at D2 post-ACA until D14 post-ACA.  This dosing range was shown to improve DA dysregulation-
driven motor impairments in PD-relevant animal models (Assini and Abercrombie, 2018).   Due 
to COVID-19 shutdown, no Sham animals were treated with zolpidem, nor ACA animals with 
chronic vehicle (0.1M PBS) injections.  For evaluating behavioral outcomes, the effects of chronic 
zolpidem administration were evaluated for low and high dose groups combined as well as 
separately for the high dose zolpidem animals. 
Injury Severity Metrics 
NDS were assigned 1, 2, and 3 days post-injury, as well as on the final day of the study 
(D7 or D14 post-injury).  Blood Lactate and ABE values were obtained at baseline as well as 5, 
30, and 60 minutes post-resuscitation.  To qualitatively assess bimodal distribution between injury 
and sham groups, as well as score range and distribution over time, histograms and scatterplots 
were generated for NDS, lactate values, and ABE values.  The median of D1 – D3 NDS were used 
for all subsequent analyses. The median among 5-, 30-, and 60-minute post-resuscitation values 
were used for all subsequent analyses.  
Statistical Analyses 
All statistical analyses were performed using either statistical analysis software (SAS) 
version 9.4 (Cary, NC, USA), Rstudio software version 3.5 (Corvallis, OR, USA), or Graphpad 
Prism version 8 (San Diego, CA, USA). Differences were considered statistically significant if p 
< 0.05, unless otherwise stated.   
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Cox Regression for Survival Analysis 
In order to investigate the effect of NDS, blood lactate, and blood ABE values on the time 
exclusion from the study, either by death or distress, takes to happen, a Cox regression was 
performed among all ACA animals (n=30).  To account for varied range between NDS, lactate, 
and ABE, their values were standardized by subtracting the mean and dividing by the standard 
deviation. 
Correlation Analyses 
Spearman’s correlations were performed to examine associations among NDS, lactate 
values, and ABE values, as well as between these injury metrics and behavioral/dopamine-related 
outcomes. Kolmogorov-smirnov (K-S) normality tests were performed for all injury, behavioral, 
and dopamine-related metrics prior to correlations.  Resulting p-values from K-S tests greater than 
0.05 for any tested data were considered to have a normal distribution.  Pearson’s correlations were 
then performed for association pairs with normal distribution, whereas Spearman’s rank 
correlations were performed for association pairs with abnormal distribution.  Due to lack of 
normality across behavioral and dopamine-related metrics, only Spearman’s rank correlations 
were performed.  To evaluate associations between dopamine-related and behavioral testing 
outcomes, partial correlation analyses were performed with NDS, lactate values, and ABE values 
included as covariates.  For all correlational analyses performed, mild associations (p=0.1-0.199, 
r=±0.3-0.499) were labeled in orange, moderate associations (p=0.01-0.09, r=±0.5-0.699) were 
labeled in green, and strong associations (p<0.01, r=±0.5-0.699) were labeled in blue. 
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Analysis of Variance/Covariance 
Analysis of variance (ANOVA) or analysis of covariance (ANCOVA) were performed to 
evaluate the differential effects of zolpidem on behavioral performance outcomes and dopamine-
related outcomes, and how they compare to those of untreated ACA animals.  Injury metrics 
which significantly correlated with the outcome-of-interest were used as covariates in the 
associated analysis.  If no injury metrics were significantly correlated with the outcome-of-
interest, ANOVA was performed.  Post hoc pairwise comparisons were assessed using Tukey’s 
test. 
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3.0 Results  
Injury Metrics Outcome Change Over Time and Are Bimodally Distributed Between Injury and 
Sham Groups  
To qualitatively assess bimodal distribution between injury and sham groups, as well as 
score range and distribution over time, histograms and scatterplots were generated for NDS (Figure 
3a-3d), lactate values (Figure 4a-4d), and ABE values (Figure 5a-5d).  
 
 
Figure 6: Scatterplots show blood lactate values for ACA (a) and Sham (b) groups at baseline, D1-D3 
(median), D7 and D14 post-surgery.  
 Overlayed histograms show bimodal distribution between ACA and Sham groups for blood lactate at D1-D3 
(median) (c) and D14 (d) post-surgery. 
 22 
 
 
Figure 7: Scatterplots show blood lactate values for ACA (a) and Sham (b) groups at baseline, D1-D3 
(median), D7 and D14 post-surgery.  
 Overlayed histograms show bimodal distribution between ACA and Sham groups for blood lactate at D1-D3 
(median) (c) and D14 (d) post-surgery. 
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Figure 8: Scatterplots show blood acid-base excess (ABE) values for ACA (a) and Sham (b) groups at 
baseline, D1-D3 (median), D7 and D14 post-surgery.  
 Overlayed histograms show bimodal distribution between ACA and Sham groups for blood ABE at D1-D3 
median (c) and D14 (d) post-surgery. 
 
Acute NDS Predicts Survival After 5-Min ACA 
NDS for days 1 – 3 post-injury were plotted for surviving ACA animals (Figure 6).  Median 
scores dropped significantly from D1 to D2 post-injury and from D1 to D3 post-injury.  
Distribution of injury metrics outcomes were also assessed for ACA survivors vs. non-survivors 
(animals excluded from the study for death or distress) (Fig. 7a-7c).  Median NDS for non-
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survivors were significantly higher compared to their survivor counterparts (Fig. 7a), whereas 
median lactate (Fig. 7b) and ABE (Fig. 7c) values were not different between groups.   
                                                   
Figure 9: Median values for NDS at D1 – D3 post-injury, represented by bars, show acute neurological 
outcome after 5min ACA.   
Paired t-tests showed a significant reduction in NDS from D1 to D2 (240.5 ± 21.98 vs. 173.8  ± 20.94, 
*p=0.0341) as well as from D1 to D3 post-injury (240.5 ± 21.98 vs. 130 ± 24.6, **p=0.0018). 
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Figure 10: Scatterplots of NDS (a), lactate (b), and ABE (c) values show differences between survivors and 
non-survivors after ACA injury. 
Median NDS for non-survivors were significantly higher compared to their survivor counterparts (Fig. 7a: 
311.6 ± 15.73 vs. 171 ± 21.94, ***p<0.0001), whereas median lactate (Fig. 7b) and ABE (Fig. 7c) values were 
not different between groups. 
 
To further explore the validity of NDS as a useful predictor of injury survival, a 
multivariable Cox regression was performed using median NDS, lactate values, and ABE values 
of animals that survived through the duration of the study and animals that were prematurely 
excluded (a.k.a. non-survivors) due to death or distress (Table 2).  The model showed that only 
(standardized) NDS was significant, in that one standard deviation (SD) increase in NDS increased 
the hazards of rats being excluded from the study (via death or being out-of-protocol) by 5.205 
times. For ABE and Lactate, the HR also increased with a 1-SD increase, but these covariates were 
not significant.   
Covariates from the multivariable Cox model were also used to estimate/predict ACA 
animal survival probabilities up to a specific post-injury timepoints (Table 3).  ACA animals had 
a 80.1% predicted survival rate up to D3 post-injury, whereas predicted survival rates up to D6 
and D7 post-injury reduced to 67.7% and 52.1%, respectively (Table 3).  Survival probability out 
 26 
to D14 post-injury matched that for D7 because no rat was excluded from the study due to death 
or weight loss after 7 days in our data. 
   
Table 2: Cox regression model of study exclusion (due to death/distress) on standardized NDS, lactate, and 
ABE median scores (n=45, number of events=25). 
NDS significantly aligned with study exclusion (HR=3.958, ***p<0.0001), but not lactate or ABE.   
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 3: Median probabilities of ACA animals surviving to 
D3, D6, and D7 post-injury. 
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Injury Metrics Correlate with Behavioral And Dopamine-Related Outcomes 
Because Kolmogorov-smirnov tests revealed non-normal distribution of relevant data 
outcomes, spearman correlations were performed to evaluate associations among injury metrics 
(Table 4), between injury metrics and DA release-based outcomes (Table 5), DA reuptake-based 
outcomes (Table 6), and between injury metrics and behavioral outcomes (Table 7).  NDS median 
values significantly correlated with long-term (D14 post-injury) NDS values (*p=0.0175, 
r=0.6565).  NDS median values also correlated with median lactate (***p<0.0001, r=0.864) and 
median ABE values (**p=0.0006, r=-0.702). 
Analyses showed moderate associations between NDS and all three ASR metrics, as well 
as both open field testing (OFT) metrics.  NDS negatively correlated with Kmi as well.  Lactate 
moderately correlated with all three ASR metrics as well as both OFT metrics.  Additionally, 
Lactate inversely correlated with total DA released, initial DA release rate (DARi), and Kmi.  ABE 
moderately correlated with all three ASR metrics, distance traveled during OFT, and sucrose 
preference testing (SPT).  ABE also correlated with evoked DA overflow, total DA released, and 
DARi.   
   
Table 4: Spearman’s rank correlations show associations between median NDS and D14 NDS, median lactate, 
and median ABE values. 
Mild (r=+/-0.3-0.499; p=0.1-0.199), moderate (r=+/-0.5-0.699; p=0.01-0.099), and strong (r=+/- 0.7-0.999; 
p<0.01) correlations are shown in orange, green, and blue, respectively. 
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Table 5: Spearman’s rank correlations show associations between injury metrics and DA release-based 
metrics. 
Mild (r=+/-0.3-0.499; p=0.1-0.199), moderate (r=+/-0.5-0.699; p=0.01-0.099), and strong (r=+/- 0.7-0.999; 
p<0.01) correlations are shown in orange, green, and blue, respectively. 
 
 
Table 6: Spearman’s rank correlations show associations between injury metrics and DA reuptake-based 
metrics. 
Mild (r=+/-0.3-0.499; p=0.1-0.199), moderate (r=+/-0.5-0.699; p=0.01-0.099), and strong (r=+/- 0.7-0.999; 
p<0.01) correlations are shown in orange, green, and blue, respectively. 
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Table 7: Spearman’s rank correlations show associations between injury metrics and behavioral outcomes. 
Mild (r=+/-0.3-0.499; p=0.1-0.199), moderate (r=+/-0.5-0.699; p=0.01-0.099), and strong (r=+/- 0.7-0.999; 
p<0.01) correlations are shown in orange, green, and blue, respectively. 
 
 
Dopamine Metrics and Behavioral Outcome Associations 
To assess functional coupling between behavioral outcomes and DA neurotransmission 
outcomes, and to evaluate any confounding or mediating effects of the established injury severity 
metrics on these outcomes after ACA, partial correlation analyses were performed among ACA 
animals.  ABE was found to be a negative confounder for two association pairs:  ASR metrics 
significantly correlated with evoked DA overflow at 1s into electrical stimulation, and these 
associations were attenuated when covarying for ABE.  Additionally, sucrose preference 
significantly correlated with maximal evoked DA and this association was strengthened by 
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covarying for ABE.  Table 8 summarizes these association pairs which changed significantly after 
adjusting for ABE. 
Table 8: Summary of association pairs from partial correlation analyses (Spearman’s rank correlations) 
which significantly changed after adjusting for ABE. 
Mild (r=+/-0.3-0.499; p=0.1-0.199), moderate (r=+/-0.5-0.699; p=0.01-0.099), and strong (r=+/- 0.7-0.999; 
p<0.01) correlations are shown in orange, green, and blue, respectively. 
 
 
Effects of Chronic Zolpidem Administration on Restoring HIBI-Induced Behavioral Deficits  
Injury metrics which significantly correlated with the outcome-of-interest after Spearman’s 
rank correlations were used as covariates in the associated analysis.  If no injury metrics were 
significantly correlated with the outcome-of-interest, ANOVA was performed.  Post hoc pairwise 
comparisons were assessed using Tukey’s test. 
Acoustic Startle Response 
Acoustic startle response (ASR) testing was performed to measure sensorimotor changes 
following HIBI on day 3 post-surgery. Untreated ACA rats showed exaggerated acoustic startle 
responses across all sound burst intensities (Fig. 8a, 8b, 8c) compared to Sham rats 3 days 
following surgery. While the ACA group showed increased responses, Sham responses decreased 
compared to their baseline scores.  The combined group of low- and high-dose zolpidem-treated 
zolpidem-treated rats (0.1mg/kg and 0.2mg/kg, respectively) did not show normalized responses 
except for the 105-dB sound bursts when combined, wherein zolpidem animals were not 
significantly different from Sham nor untreated ACA animals (Fig. 8a-8c).  High dose (0.2mg/kg) 
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zolpidem-treated rats, when evaluated on their own (Fig. 8d-8f), exhibited significantly lower 
responses for 95-dB and 105-dB sound bursts compared to untreated ACA animals (Fig. 8e-8f). 
 
 
Figure 11: Mean ± SEM for acoustic startle responses at 85 dB (8a, 8d), 95 dB (8b, 8e), and 105 dB (8c, 8f) 
sound bursts shown as a percent change from baseline to 3 days post-surgery. 
(a) ANCOVA showed a main effect of group (**p=0.0009), but no effect of NDS median, lactate median, or 
ABE median.  Post hoc Tukey’s test show significant differences between 2wk ACA and 2wk Sham groups 
(**p=0.0002). (d) ANCOVA showed a main effect of group (**p=0.0009), but no effect of NDS median, lactate 
median, or ABE median.  Post hoc Tukey’s test show significant differences between 2wk ACA and 2wk 
Sham groups (**p=0.0002), as well as between 2wk ACA ambien and 2wk Sham groups (*p=0.0365).  (b) 
ANCOVA showed a main effect of group (**p=0.0065), but no effect of NDS median, lactate median, or ABE 
median.  Post hoc Tukey’s test show significant differences between 2wk ACA and 2wk Sham groups 
(**p=0.0017), as well as between 2wk ACA ambien and 2wk Sham groups (*p=0.0221). (e) ANCOVA showed 
a main effect of group (**p=0.0065), but no effect of NDS median, lactate median, or ABE median.  Post hoc 
Tukey’s test show significant differences between 2wk ACA and 2wk Sham groups (**p=0.0017) as well as 
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2wk ACA and 2wk ACA ambien group (*p=0.0128). (c) ANCOVA showed a main effect of group 
(*p=0.0246), but no effect of NDS median, lactate median, or ABE median.  Post hoc Tukey’s test show 
significant differences between 2wk ACA and 2wk Sham groups (**p=0.0015). (f) ANCOVA showed a main 
effect of group (*p=0.0246), but no effect of NDS median, lactate median, or ABE median.  Post hoc Tukey’s 
test show significant differences between 2wk ACA and 2wk Sham groups (**p=0.0007), as well as 2wk ACA 
and 2wk ACA ambien group (*p=0.0147). 
 
Myoclonus Testing 
Myoclonic responses were measured at day 2 post-surgery for untreated ACA, zolpidem-
treated ACA, and Sham animals (Figure 9).  Untreated ACA rats showed a marked increase in the 
percent of myoclonic response compared to Sham group.  Neither zolpidem-treated group showed 
a reduction in myoclonic responses compared to untreated ACA animals (Figure 9a,9b).   
 
Figure 12: Mean ± SEM values for myoclonic responses observed D2 following ACA/sham surgery. 
(a) ANOVA showed significant differences across groups (**p=0.0025).  Post hoc Tukey’s test showed 
significant differences between 2wk ACA and 2wk Sham groups (**p=0014), as well as between 2wk Sham 
and 2wk ACA ambien groups (**p=0.0048).  (b) ANOVA showed significant differences across groups 
(**p=0.0025).  Post hoc Tukey’s test showed significant differences between 2wk ACA and 2wk Sham groups 
(**p=0.0007), as well as between 2wk Sham and 2wk ACA ambien groups (**p=0.016). 
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Open Field Testing 
Mobility (Figure 10) and exploratory behavior (Figure 11) were assessed via open field 
testing (OFT) on day 7 post-ACA/Sham surgery for untreated ACA, zolpidem-treated ACA, and 
Sham animals.  ACA significantly reduced both the distance traveled (Fig. 10) and number of 
entries to the exploratory zone (Fig. 11) compared to Sham animals.  The combined group of low 
and high dose zolpidem-treated animals showed no significant improvements in the distance 
traveled (Fig. 10a) nor exploratory zone entries compared to untreated ACA animals (Fig. 11a).  
High dose zolpidem-treated animals exhibited a modest increase in the distance traveled (Fig. 10b), 
though also not different from shams.  Additionally, the high dose zolpidem group showed a slight 
reduction in exploratory zone entries compared to untreated ACA animals, though not significant 
(Fig. 11b).   
 
Figure 13: Mean ± SEM values for distance traveled in the OFT D7 post-surgery. 
(a) ANCOVA showed a main effect of group (*p=0.0264) as well as a main effect of NDS median 
(**p=0.0021).  Post hoc Tukey’s test show significant difference between 2wk ACA and 2wk Sham group 
(*p=.0192).  (b) ANCOVA showed a main effect of group (**p=0.0088) as well as a main effect of NDS median 
(**p=0.0053).  Post hoc Tukey’s test show significant difference between 2wk ACA and 2wk Sham group 
(*p=.0103). 
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Figure 14: Mean ± SEM values for exploratory zone entries in the open field D7 post-surgery. 
(a) ANCOVA showed a main effect of group (**p=0.0058) as well as a main effect of NDS median (*p=0.03).  
Post hoc Tukey’s test show significant difference between 2wk ACA and 2wk Sham group (**p=.0046), as 
well as between 2wk ACA ambien and 2wk Sham groups (**p=0.0045).  (b) ANCOVA showed a main effect 
of group (**p=0.0011) as well as a main effect of NDS median (*p=0.0115).  Post hoc Tukey’s test show 
significant difference between 2wk ACA and 2wk Sham group (**p=.0032), as well as between 2wk ACA 
ambien and 2wk Sham groups (**p=0.0025). 
 
Sucrose Preference Testing 
To assess anhedonia after ACA, sucrose preference testing (SPT) was performed on day 8 
post-ACA/sham surgery for untreated ACA, zolpidem-treated ACA, and Sham animals. ACA 
caused a significant decrease in sucrose preference which was reversed in the high dose zolpidem-
treated animals (Fig. 12b).  The combined group of low and high dose zolpidem-treated animals 
was not significantly different from Sham nor untreated ACA animals (Fig. 12a).  
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Figure 15: Mean ± SEM of sucrose preference calculated on D8 post-surgery. 
(a) ANCOVA showed no main effect of group, though it did show a main effect of ABE median (*p=0.0327).  
Post hoc Tukey’s test showed a significant difference between 2wk ACA and 2wk Sham groups (*p=0.0482). 
(b) ANCOVA showed a main effect of group (*p=0.0477) and a slight main effect of ABE median (p=0.0517).  
Post hoc Tukey’s test showed a significant difference between 2wk ACA and 2wk Sham groups (*p=0.0428) 
and a trend towards differences between 2wk ACA and 2wk ACA ambien groups (#p=0.088). 
 
Effects of Chronic Zolpidem on Voltammetric Responses and Evoked DA Overflow in The 
Dorsal Striatum After ACA-Induced HIBI 
For all voltammetric data, the low and high dose zolpidem-treated animals were combined 
into one group.  Electrically stimulated DA responses reflect a balance of DA release and reuptake 
kinetics. Figure 13 shows the average DA responses in the dorsal striatum (D-STR) for untreated 
ACA, zolpidem-treated ACA, and Sham animals following a maximal 60 Hz, 10 s stimulation of 
the medial forebrain bundle (MFB).  Responses were obtained at day 14 post-ACA/Sham surgery. 
Maximal evoked DA overflow was significantly increased during and after stimulation in the ACA 
group compared to the Sham group at 2 weeks post-surgery (Fig. 13a).  Chronic zolpidem 
administration seemed to reduce maximal evoked DA in that treated animals were not significantly 
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different from untreated ACA nor Sham groups (Fig. 13a).  Evoked DA at 1s into the stimulation 
was also assessed among groups, though ANCOVA showed no significant differences (Fig. 13b).   
 
Figure 16: Mean ± SEM of maximal evoked DA overflow (a) and evoked DA overflow 1s into stimulation (b) 
in the D-STR following 60Hz, 10s MFB stimulations two weeks post-surgery. 
  (a) ANOVA showed significant main effect of group (p=0.0044).  Post hoc Tukey’s test showed significant 
difference between 2wk ACA and 2wk Sham groups (**p<0.01).  (b) ANCOVA showed no significant 
differences across groups. 
 
Effects of Chronic Zolpidem on ACA-Induced DA Kinetics Alterations 
In order to measure DA kinetics in the D-STR, FSCV data were modeled using the QN 
framework as described previously described.  Figure 14 shows group comparisons for DA 
release-based metrics for untreated ACA, zolpidem-treated ACA, and Sham animals at day 14 
post-ACA/Sham surgery.  QN simulations revealed that total [DA] release (Fig. 14a), initial DA 
release rate (DARi) (Fig. 14b), were significantly increased in both untreated and zolpidem-treated 
ACA groups compared to Shams.  
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Figure 17: Mean ± SEM values of total DA released (a) and initial DA release rate (b) in the D-STR following 
60Hz,10s stimulation two weeks post-surgery. 
(a) ANCOVA showed main effect of group (**p<0.0011), but no main effect of Lactate median or ABE 
median.  Post hoc Tukey’s test show significant differences between 2wk ACA and 2wk Sham groups 
(***p<0.0001), as well as between 2wk ACA zolpidem and 2wk Sham groups (**p=0.0017).  (b) ANCOVA 
showed main effect of group (**p<0.0002), but no main effect of Lactate median or ABE median.  Post hoc 
Tukey’s test show significant differences between 2wk ACA and 2wk Sham groups (***p<0.0001), as well as 
between 2wk ACA zolpidem and 2wk Sham groups (**p=0.0025). 
 
Figure 15 shows group comparisons for DA reuptake-based metrics for untreated ACA, 
zolpidem-treated ACA, and Sham animals at day 14 post-ACA/Sham surgery.  QN simulations 
revealed that maximal velocity of DA reuptake (Vmax) from 60 Hz, 10 s stimulations was 
significantly increased in both untreated and zolpidem-treated ACA groups two weeks post-injury 
(Fig. 15a) while Kmi remained unchanged for both ACA groups compared to Sham animals (Fig. 
15b). 
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Figure 18: Mean ± SEM maximal DA reuptake velocity (Vmax) (a) and Kmi (b) for each group. 
 (a) ANOVA showed significant main effect of group (***p<0.0001) for Vmax.  Post hoc Tukey’s test showed 
significant differences between 2wk ACA and 2wk Sham groups (**p=0.0004), as well as between 2wk ACA 
zolpidem and 2wk Sham groups (*p=0.0238).  (b) ANCOVA showed no significant differences across groups 
for Kmi. 
 
 
39 
4.0 Regional Zolpidem Microinjections to Reverse HIBI-Induced Striatal 
Hyperdopaminergia – A Conceptual Experiment 
Introduction 
HIBI affects certain brain regions more than others.  Striatal medium spiny neurons 
(MSNs), particularly those expressing D2 receptors (D2Rs), are particularly vulnerable to ischemic 
damage and exhibit early, irreversible damage from ischemia19.  Striatal MSNs also receive dense 
DAergic input from the substantia nigra pars compacta (SNpc) and evidence shows uncontrolled 
DA release seen after even a mild hypoxic-ischemic insult, which is more severe than ischemia‐
induced increases of other neurotransmitters27,28. Through their modulation of cortical, thalamic, 
and limbic glutamatergic input, as well as aspiny striatal acetylcholine (ACh) interneurons, MSNs 
play key roles in cognition, behavior, motivation, and controlled movement.  Aberrant DA 
signaling underlies various movement disorders, such as in Parkinson’s disease (PD) and 
Huntington’s disease (HD)29, suggesting DA neurotransmission changes after CA may facilitate 
HIBI-induced motor abnormalities.  The thalamic reticular nucleus (tRN) is also particularly 
vulnerable to ischemic injury and animal CA models have demonstrated hyperactive 
thalamocortical signaling70.  Another primarily GABAergic region, the tRN provides inhibitory 
modulation of the intralaminar (iLN) thalamus83, a crucial component of the reticular activating 
system (RAS) which, through its communication with the cortex, regulates conscious states84.  
HIBI-induced neuronal damage in the tRN likely facilitates abnormal thalamocortical signaling 
that drives DoC after CA. 
Striatal MSNs project topographically to the internal and external globus pallidus (GPi and 
GPe, respectively) as part of the “direct” and “indirect” pathways of movement, and SNc DAergic 
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afferents influence these pathways through their effect on different DA receptors.  DA exerts an 
excitatory effect on D1R-expressing MSNs (of the “direct” pathway) and an inhibitory effect on 
D2R-expressing MSNs (of the “indirect” pathway)85.  Aspiny ACh interneurons modulate these 
effects by acting as pacemakers, tonically regulating striatal MSN output86,87. DA Striatal MSNs 
also project to the substantia nigra pars reticulata (SNpr) and SNpc88,89.  Striatal DA release by 
dopaminergic SNpc projections are regulated in part by direct and indirect GABAergic feedback 
from MSNs33–35 and this GABAergic control of the SNc strongly influences its firing properties34.  
GABAergic afferents from the GPe also strongly influence the firing properties of both nigral 
regions34,36,37. Disrupted GABAergic outflow resulting from MSN damage or dysfunction may 
facilitate striatal hyperdopaminergia as well as abnormal thalamocortical transmission that 
manifests itself as movement and hypo-arousal disorders.   
Recent clinical evidence highlights zolpidem, otherwise known as Ambien, as an effective 
therapy to treat post-HIBI symptoms63,65. Though a well-known hypnotic agent, a growing body 
of research has studied zolpidem as a tool to promote emergence from DoC, and clinical evidence 
shows that a short course of zolpidem treatment acutely following HIBI from CA can lead to 
paradoxical improvements in arousal61,63–65.  Zolpidem is a GABAA receptor agonist with a high 
selectivity for those expressing the 1 subunit.  These receptors, expressed in the striatum, GP, 
SN, and thalamic nuclei exert a direct influence on striatal DA neurotransmission and 
thalamocortical signaling69.  Zolpidem administration has been linked to improvement in 
Parkinson’s associated movement disorders66,67, possibly by inhibiting GPi-induced 
thalamocortical hyperactivation and/or other sites where GABA-A receptor inhibition impacts DA 
transmission directly, such as the SNpr and SNpc69.  However, the paradoxical response to 
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zolpidem after brain injury is largely theoretical68,90, and its clinical use has been met with highly 
mixed results72–76.   
The results from our preliminary study detailed in the previous aim also show mixed effects 
of chronic systemic zolpidem administration on improving outcome after CA.  FSCV findings 
show a modest decrease in evoked striatal DA after chronic zolpidem treatment.  High dose 
zolpidem (0.2mg/kg daily) normalized acoustic startle responses and reversed anhedonia as 
represented by increased sucrose preference.  However, other DA release-based metrics as well as 
DA clearance/reuptake metrics remained unchanged, and the occurrence of myoclonus and 
exploratory behavior remained relatively unchanged.  Interestingly, the higher dose of zolpidem 
administered resulted in a dichotomy of outcomes for both myoclonus and open field testing, 
resembling a group of “responders” and one of “non-responders” with regard to treatment. One 
explanation is that GABAA α-1 receptor density varies across the regions where they are localized.  
For example, they are expressed in higher concentration in the GP compared to the striatum91. 
Taken with the GABAA α-1 receptor’s expression within several basal ganglia regions, systemic 
zolpidem may exert different downstream effects depending on where it binds these receptors.   
Characterizing zolpidem’s effects when localized to particular regions of the striatal-
pallidal-thalamocortical circuitry may elucidate the influence these different regions have in 
mediating HIBI-induced neurological sequelae, as well as assess the efficacy of GABAA α-1 
receptors as a therapeutic target for treating hyperdopaminergia and associated behavioral deficits 
after ACA. This conceptual study evaluates the presumed impacts of zolpidem microinjections 
into the GPe in a rat model of asphyxia cardiac arrest (ACA). Given the modest reductions in 
evoked striatal DA seen in the previous aim and the GPe’s high concentration of GABAA α-1 
receptors, perhaps systemic zolpidem exerted its mildly beneficial effects through this region.  As 
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such, it is hypothesized that intra-pallidal zolpidem may “replace” functions of 
dysfunctional MSNs and normalize striatal GABAergic outflow to the SNpr and SNpc, 
thus restoring GABAergic feedback to nigral DAergic neurons and reversing striatal 
hyperdopaminergia.   
Methods 
Prior to surgical procedures, rats will be housed in pairs, then housed alone 
following recovery from the surgeries. Rats will be granted unrestricted access to food and water 
as well as a 12 h light/dark cycle.  Rats will be randomly assigned to one of the following groups 
outlined in Table 1 below.  Microinjections will be performed for groups of n=6 for ACA 
animals, and n=4 for sham/naïve animals, based on previous studies employing 
regional zolpidem microinjections92,93. Rats assigned to the ACA or sham group will undergo 
identical surgical and post-operative procedures as described in prior sections of the thesis.  
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Table 9: Injury and treatment group counts. 
Injury Group Treatment Microinjection 
(GPe) 
ACA Vehicle (DMSO 
+ aCSF) 
N=6 
Sham Vehicle (DMSO 
+ aCSF) 
N=4 
Naive Vehicle (DMSO 
+ aCSF) 
N=4 
ACA Zolpidem N=6 
Sham Zolpidem N=4 
Naive Zolpidem N=4 
 
Fast Scan Cyclic Voltammetry 
Two weeks following ACA / Sham procedures, rats will undergo fast scan cyclic 
voltammetry (FSCV) to measure regional variations of DA neurotransmission based on previously 
used methods5, but with modifications appropriate for this experiment.  Experimental DA 
responses will be obtained using alternating 60- and 40 Hz stimulations for 5- or 10 s according to 
the schematic depicted in Figure 1. For data analysis purposes, 5- and 10 s recordings at 60 Hz 
stimulation will be applied prior to any drug or vehicle microinjection. We then applied 60 Hz, 5 
s stimulations at 10- and 35 min after vehicle or zolpidem infusion as well as 40 Hz 5 s stimulations 
at 25- and 50 min after vehicle or zolpidem infusion.  
Following in vivo electrode measurements, electrodes will be calibrated with seven DA 
concentrations in artificial cerebrospinal fluid (pH = 7.2) composed of (in mM): 1.2 CaCl2, 2.0 
Na2HPO4, 1.0 MgCl2, 2.7 KCl, and 145 NaCl80. The DA concentration versus current calibration 
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using a quadratic regression will be used to convert experimental DA responses from measured 
currents to DA concentrations. 
 
 
Figure 19: Schematic representation of FSCV experimental study and microinjection timepoints. 
 
Regional Microinjections 
 
 While under urethane anesthesia associated with FSCV.  Midline incisions will be made, 
and soft tissues lifted to expose the skull, at which point burr holes will be drilled contralaterally 
to CFE burr hole for the placement of a microsyringe needle.  A craniotomy will be performed at 
coordinates 1.0-2.0 mm posterior and 3.0-4.0 mm lateral from bregma81,94 for needle placement 
into the GPe.   
At the end of baseline FSCV procedures, rats will be implanted with a 32-g stainless steel 
cannula (Hamilton). A micro-syringe (Hamilton) will be connected through the cannula to an 
infusion pump (World Precision Instruments) and lowered into the brain.  The needle will be 
lowered to the following coordinates (relative to bregma) for GPe microinjection: AP: -1.4 mm; 
ML: 3.6mm; DV: -6.6mm94. 100nM or 1mM of zolpidem93 dissolved in 2uL vehicle (80% aCSF, 
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20% DMSO), or 2uL vehicle (aCSF) will be infused into the GPe at a rate of 0.5uL/min.  The 
needle will be left in place for another 3 minutes to ensure compound diffusion. 
Verification Of Stereotaxic Coordinates 
Following FSCV procedures, regional microinjection sites will be verified using Evans 
Blue dye.  2uL of Evans Blue dye will be infused into the GPe at a rate of 0.5uL/min and the needle 
will be left in place for another 2 minutes to ensure compound diffusion before removing the 
needle, electrodes, and temperature probes.   
Rapid decapitation will be performed using a guillotine and the brain will be extracted 
from the skull using surgical rongeurs before drop-fixing in 10% formalin.  After 48 hrs, the 
brain will be placed in a rat brain slicer matrix (Kent Scientific), and 1mm coronal sections 
will be cut.  Correct infusion location will be verified using a rat brain axis81 and regional 
landmarks as reference such as the striatum’s striped appearance or the prominence of the 
third and lateral ventricles relative in the slices relative to those in the neuroanatomical atlas.  
Only animals which have had correct infusion locations verified will be added as viable data. 
Proposed Results 
HIBI results in damage or dysfunction of metabolically vulnerable MSNs, effectively 
damaging one of the primary sources of inhibition on SNpc DAergic neurons34.  To help replace a 
function of these dysfunctional MSNs, GPe microinfusion of GABAA α-1 receptor agonist, 
zolpidem, was proposed.  In ACA animals, zolpidem infusion would presumably decrease GPe 
outflow due to its relatively dense population of GABAA α-1 receptors.  Given the degree of GPe 
projections to SNpc DAergic neurons34,36,95, this decreased pallidal outflow could potentially 
exacerbate striatal hyperdopaminergia via their disinhibition.  It is hypothesized that lower dosages 
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of zolpidem in the GPe would elicit this harmful effect. However, the GPe strongly influences the 
firing properties of both nigral regions34,36 and the firing pattern of SNpc DA neurons is largely 
modulated by SNpr GABAergic neurons37.  Further, nigral GABAergic neurons are more sensitive 
to GABAA-mediated inhibition than nigral dopaminergic neurons, in part due to a more 
hyperpolarized GABAA reversal potential37.  Therefore, decreasing pallidal inhibitory drive 
should disinhibit these SNpr GABAergic neurons, and consequently increase their inhibitory drive 
onto DAergic SNpc neurons, thus reversing post-HIBI striatal hyperdopaminergia.  It is expected 
that this effect would result from larger doses of intra-GPe zolpidem. 
In terms of the voltammetric signals obtained from the FSCV experiment, inhibition of 
SNpc DAergic neurons would be represented as reduced amplitude and concentration of evoked 
DA, as well as a reduction in the initial DA release rate.  With regard to DA clearance and reuptake, 
an acute drug challenge may not be evident via reduced velocity of DA reuptake (Vmax).  5-min 
VF-CA animal models show a considerable upregulation of striatal DA transporter (DAT) as well 
via western blot analysis.  Concurrently, western blot analysis of experimental TBI models, which 
suggest a functional hypo-dopaminergia, show a corresponding decrease in Vmax and striatal 
DAT expression, suggesting that chronic changes in Vmax may occur as a compensatory 
mechanism to combat aberrant DA neurotransmission. Sham and Naïve animals would 
presumably react differently to intra-GPe zolpidem because they still retain normal striatal 
GABAergic outflow.  Further inhibiting the GPe may result in a suppression of striatal DAergic 
tone due to disinhibition of SNpr GABAergic neurons, and the corresponding voltammetric 
readouts in these animals may resemble the diminished DA neurotransmission observed in 
experimental TBI models.  However, zolpidem in the GPe will inhibit a combination of SNpr 
neurons and SNpc DAergic neurons.  At smaller doses, zolpidem may exert minimal effects on 
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striatal DA neurotransmission due to its mixed actions on SNpr and SNpc neurons combined with 
the striatal MSN inhibitory drive on SNpc DAergic neuron firing.  For any injury group, vehicle 
injections should exert minimal effects on voltammetric DA responses compared to animals not 
receiving any microinjections, and resemble similar responses observed for 5min- ACA, Sham, or 
Naïve animals6. 
Discussion  
This study evaluated the proposed effects of GABAergic modulation of the GPe, via 
zolpidem microinfusion, to reverse striatal hyperdopaminergia stemming from a 5-min ACA.  It 
is hypothesized that larger doses of intra-GPe zolpidem will help reverse striatal 
hyperdopaminergia by disinhibiting SNpr GABAergic neurons thus indirectly inhibiting SNpc 
DAergic neuronal firing, as described in figure 20. 
 
Figure 20: Proposed effects of intra-pallidal zolpidem 
Zolpidem microinjections into the GPe may disinhibit SNpr GABAergic neurons, thus re-introducing 
inhibitory drive onto SNpc DAergic neurons and reversing striatal hyperdopaminergia. 
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However, these DAergic neurons receive afferent input from other regions which 
complicate the effects of GPe modulation on SNpc neuronal firing.  The subthalamic nucleus 
(STN), another main output target of the GPe and a primarily glutamatergic region, may play a 
role in regulating DAergic neuron firing through NMDA receptor stimulation96–98. GPe inhibition 
will disinhibit the STN which may counteract the previously proposed effects of intra-GPe 
zolpidem on DAergic neuron firing. 
HIBI’s long-term effects on the basal ganglia circuitry should also be considered.  In 
addition to striatal, pallidal, and thalamic neuron damage/dysfunction, ischemic injury also 
delayed damage to SNr GABAergic neurons as early as three weeks following injury99.  As these 
neurons are the primary source of inhibition on nigral DAergic neurons, delayed SNr damage post-
HIBI likely exacerbates SNc disinhibition after the injury.  However, SNpr damage might allow 
other SNpc afferents to exert more influence over DAergic neuron firing, such as the smaller 
population of SNpc GABAergic neurons.   
In addition to striatal hyperdopaminergia that likely underlies post-HIBI motor 
impairments, CA survivors commonly suffer from DoC likely due to abnormal thalamocortical 
signaling mediated by tRN damage.  The tRN also has a very dense GABAA α-1 receptor 
population even compared to the GP91, further suggesting the idea that systemic zolpidem 
administration affects several different regions and at different capacities, which may explain the 
mixed effects of systemic zolpidem observed in animal models and clinical studies.   
Future work should evaluate the effects of intra-thalamic zolpidem injections as they may 
help replace the function of damaged tRN GABAergic neurons after CA.  Rather than FSCV, these 
studies could utilize electrophysiology techniques to evaluate changes in thalamocortical neuronal 
firing after intra-thalamic zolpidem administration. Additional work should continue exploring the 
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differential effects of systemic zolpidem administration vs. microinfusions at varied post-HIBI 
timepoints, and this can be done in concert with neuronal tissue staining and western blot analyses 
to further characterize the time-course of neuronal damage and protein expression changes that 
mediate HIBI-relevant symptomologies.  Though microinfusions pose practical obstacles for 
treating clinical populations, their use may offer key mechanistic insights to HIBI-induced 
neuronal dysregulation brought that drives motor and cognitive impairments, thus highlighting 
other therapeutic targets for treating CA survivors. 
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5.0 Discussion 
Cardiac arrest produces global cerebral ischemia that commonly results in HIBI among 
survivors.  Though limited, the use of acute neurological and physiological readouts suggests 
promise as prognostic tools for ischemic injuries, so we evaluated their utility in predicting long-
term behavioral outcomes.  HIBI results in disruptions DA neurotransmission, which under 
physiologic conditions, mediate motor, cognitive, and behavioral functions.  As such, how these 
injury severity readouts align with electrically stimulated DA neurotransmission outcomes was 
also explored.   
These results show that a neurological readout, as defined by the neurological deficit score, 
is a valuable predictor of survival after a 5-min ACA.  When comparing values between survivors 
and non-survivors, only NDS showed a significant difference of the three metrics evaluated, 
suggesting that acute mortality after the ACA is likely due to neurological injury rather than 
cardiovascular injury.  The Cox regression showed increases in NDS increase the hazard ratio of 
protocol exclusion either by death or severe distress by almost 40%.  NDS, lactate, and ABE 
covariate data from the Cox regression were also used to predict survival probabilities up to a week 
post-injury.  Even as estimated values, these prediction data may prove useful to pre-clinical 
technicians for honing experimental CA models.  Acute NDS was also significantly correlated 
with day 14 post-injury NDS, further suggesting their utility in predicting long-term neurological 
outcome after ACA.   
Spearman’s rank correlations showed associations between DA release-based metrics and 
lactate, and ABE, respectively, suggesting that these physiological readouts may align with ACA-
induced deficits at a more granular level than NDS.  Though ABE serves as a prognostic tool in a 
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clinical setting, the experimental ACA surgery procedure may influence these data.  For example, 
intravenous bicarbonate is administered to promote return-of-spontaneous-circulation (ROSC) by 
directly combating acidosis caused by the cardiac arrest.  As ABE is an inverse measure of 
acidosis, this resuscitation tool likely influences acute ABE values. 
Because DA neurotransmission abnormalities are likely related to commonly observed 
cognitive and behavioral impairments after HIBI, partial correlation analyses were employed to 
identify functional coupling between them before and after adjusting for NDS, lactate values, and 
ABE values.  The 85-dB and 95-dB sound bursts in the ASR assessment positively correlated with 
evoked DA at 1s (into electrical stimulation).  Sucrose preference inversely correlated with 
maximal evoked DA as well, suggesting a functional coupling between DA release-based metrics 
and behavior, in addition to physiological readouts.  Further, adjusting for ABE as a covariate 
attenuated the associations between ASR metrics and evoked DA at 1s, while strengthening the 
inverse association between sucrose preference and maximal evoked DA.  As described above, 
however, the influence ABE exerts over these long-term associations should be considered as a 
potential confound in an experimental CA setting. 
The neurological injury induced by circulatory arrest determines a patient’s prognosis after 
CA, and these injury-induced changes in cerebral blood flow (CBF) affect neuronal bioenergetics 
and result in neuronal damage/dysfunction that may drive DA neurotransmission and behavioral 
abnormalities.  Post-CA CBF properties also change over time which may drive neuronal damage 
and dysfunction100.  Cerebral perfusion after resuscitation is characterized by early hyperemia 
followed by hypoperfusion and, ultimately, restoration of normal blood flow approximately 72 hrs 
following resuscitation100.   At the level of microcirculation, CBF is heterogeneous and 
characterized by areas of no flow, low flow, and increased flow in certain brain regions101, such as 
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the “no flow phenomenon” observed, via animal models, in cortical capillaries101.  CBF directed 
therapies tested in animal CA models, such as the use of albumin102, have improved neurological 
outcome, suggesting that post-CA CBF alterations contribute to the development of HIBI.  
However, little work has been done in the clinical population for utilizing CBF directed therapies 
to improve neurological outcome after CA101.  Although the present study focused on the two-
week post-injury timepoint, preliminary data from our lab (not shown) shows dynamic changes in 
DA neurotransmission over time following HIBI. The energy deficiency caused by HIBI leads to 
a breakdown in neuronal concentration gradients, allowing for calcium influx that drives 
mitochondrial damage and cell death103.  Bioenergetic changes following HIBI may alter MSN 
activity as well, leading to dynamic changes in DA neurotransmission over time.  In the acute post-
injury phase, The HIBI-induced blood flow disruptions deprive MSNs of their energy reserves 
quickly due to their high metabolic demands, eliciting a rapid dissolution of their electrochemical 
gradients and cell depolarization104.  The resulting high MSN activity drives inhibition to MSN 
target regions including the GP and the SNpc, the latter of which may inhibit DA 
neurotransmission and lower striatal DA levels.  As these brain regions slowly recover from the 
initial injury, compensatory changes may continue to drive DA neurotransmission changes and 
dynamic neuronal dysfunction.  Future research should verify the rate at which HIBI depletes MSN 
energy reserves and how MSN depolarization impacts DA release.  Further, research should 
characterize MSN bioenergetic properties over time to elucidate their changes and how they may 
impact striatal DA neurotransmission over time. 
The neurobiological mechanisms underlying depression are not well understood.  
Depression symptoms like anhedonia implicate a number of highly interconnected brain regions, 
making it difficult for clinicians and researchers to elucidate its molecular mechanisms105.  HIBI 
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disrupts multiple brain areas directly and indirectly implicated in depression.  Researchers 
highlight the potential role of striatal DA aberrations as a potential mediator of depression 
symptoms. Early hypotheses have suggested a link between DA deficiency and depression because 
past research showed beneficial effects of dopamine precursors and agonists on ameliorating 
depressive symnptoms106.  The effects of experimental TBI generally align with this hypothesis, 
as TBI induces a suppression of striatal DA neurotransmission5, and post-TBI depression is well 
documented in clinical practice.  However, the results at hand show a robust state of striatal 
hyperdopaminergia as well as anhedonia after a 5-min ACA.  Additionally, the large inverse 
correlation between sucrose preference and maximal evoked DA derived from partial correlation 
analyses suggests that anhedonia increases in severity as striatal DA increases.   
A large body of animal research focuses on the hippocampus and frontal cortical regions 
as key mediators of depression107, both of which are selectively vulnerable to HIBI.  There is some 
evidence of reduced hippocampal volumes in depressed or PTSD patients108.  As the hippocampus 
exerts inhibitory control over the hypothalamic-pituitary-adrenal (HPA) axis, a decline in 
hippocampal function may contribute to hypercortisolemia observed in a population of depressed 
patients109,110.  One study used positron emission tomography to identify abnormal hippocampal 
and cortical blood flow in depressed individuals111.  The thalamus may also contribute to post-
HIBI depression.  Neuronal damage in the thalamic reticular nucleus (tRN), brought on by global 
ischemia, leads to elevated firing rates of thalamocortical neurons70, and impaired thalamocortical 
connectivity with the prefrontal and anterior cingulate cortices (aCC) facilitates disorders of 
consciousness112.  Considering the aCC’s role in emotion processing, morality, impulse control, 
and other limbic behaviors, altered thalamocortical signaling after HIBI may mediate depression 
symptoms.   
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In addition to mechanical damage and neuronal dysfunction, brain injuries also elicit severe 
inflammatory responses which potentially drive a number of symptoms.  Sickness behaviors refer 
to behavioral changes that result from central neural activity changes.  These behaviors are often 
encountered during acute systemic infections and are an important adaptive survival 
mechanism113.  Depression is among the most common symptoms accompanying traumatic brain 
injuries114,115.  The high incidence of sickness behaviors with systemic inflammatory diseases 
occurring outside the CNS suggests that their association with these ischemic brain injuries is in 
part driven by inflammation.  With HIBI and its effects on basal ganglia circuitry, inflammation 
can strongly impact multiple parameters associated with striatal DA neurotransmission and affect 
functional connectivity between brain regions that behaviors including motor activity, depression, 
and anxiety43,44,116.  Experimental models of ventricular fibrillation cardiac arrest (VF-CA) 
demonstrate persistent striatal Iba staining46, suggesting striatal microglial activation in response 
to VF-CA.  Robust increases in tumor necrosis factor-alpha (TNFa) are also seen in the striatum 
after VF-CA46,117.  Taken with the minimal changes in striatal protein expression observed after 
VF-CA6, one hypothesis for hyperdopaminergia and the associated anhedonia/depression is 
ongoing neuroinflammation.   
The acoustic startle circuit is a reflexive, tri-synaptic pathway primarily localized to the 
pons and the spinal cord53,118.  Auditory information is translated into neural signals at the cochlear 
nuclei.  The cochlear nuclei then relay these signals via the 8th cranial nerve to the pontine reticular 
nucleus (PnC), a key contributor to sensorimotor integration and plasticity of the acoustic startle 
reflex (ASR)51,52.  PnC projections innervate hundreds of motor neurons, via the reticulospinal 
tract in the medial longitudinal fasciculus of the spinal cord, in response to the stimulus.   
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However, ASR disruptions are associated with neurological disorders like TBI and 
schizophrenia, which are not directly involved with this primary circuitry, and implicate aberrant 
DA signaling in these secondary brain regions.  TBI induces long-lasting ASR suppression without 
prompting degeneration of its essential neural circuit47. TBI does induce hippocampal and cortical 
cell death, however, suggesting that a primary cortical impact can influence brainstem circuit 
function.  Additionally, striatal DA neurotransmission suppression associated with experimental 
TBI models corroborates the idea that dopaminergic signaling directly influences the ASR.  
Other neurological disorders such as schizophrenia are characterized by overactive DA 
systems and dysregulated cortical-striatal circuitry and result in ASR hypersensitivity and PPI 
deficits48,49.  Our study demonstrated that a 5-min ACA results in ASR hypersensitivity and PPI 
deficits three days following the injury, and that ASR metrics correlated with evoked DA metrics, 
corroborating this positive relationship between ASR and DA signaling.  HIBI results in 
damage/dysfunction of metabolically vulnerable MSNs, particularly those expressing D2Rs, likely 
reducing striatal GABAergic outflow.  In turn, the globus pallidus loses a main source of inhibitory 
input, and the resulting increase in pallidal outflow indirectly disinhibits SNpc DAergic neurons.  
Recent studies utilizing tract tracing methods demonstrate that the SNpc directly exerts 
dopaminergic tone on the PnC119 in addition to its striatal and cortical projections, offering a 
potential mechanistic link for amplified ASR after ACA-induced HIBI. 
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Figure 21: Schematic of acoustic startle response pathway influenced by HIBI 
Ischemia-induced MSN dysfunction disinhibits the GP and indirectly leads to increased firing of SNpc 
DAergic neurons.  Because the SNpc directly innervates the PnC, a key region for mediating the acoustic 
startle response, HIBI may result in amplified acoustic startle responses due to increased SNpc outflow. 
 
 
Myoclonus refers to sudden, involuntary muscle jerks, shakes or spasms, and these 
abnormal involuntary movements are a hallmark feature of post-HIBI symptomologies. 
Mechanisms underlying post-hypoxic myoclonus (PHM) are not well understood but 
thought to arise due to neuronal hyperactivity following the ischemic brain injury120–122.  As such, 
antiglutamatergic and anticholinergic agents have been tested with some success to attenuate PHM 
in animal CA models, and to promote neuroprotection of hippocampal and cerebellar 
neurons123,124. Piracetam is a GABA derivative but through its modulatory actions on a range of 
neurotransmitter systems including cholinergic and glutamatergic, exerts robust anti-myoclonic 
effects in animal CA models and in humans124,125.  Though multiple therapeutic agents tested have 
successfully attenuated PHM, the neurobiological mechanisms underlying PHM and audiogenic 
seizures remain poorly understood.  One explanation for PHM is cerebellar damage, particularly 
the purkinje neurons, following ischemic brain injury. Basal ganglia circuits were considered to 
be anatomically and functionally distinct from cerebellar circuits126, but a number of subsequent 
 57 
studies challenge this perspective.  A disynaptic projection between the cerebellar dentate nucleus 
and dorsal striatum have been described using retrograde transneuronal transport methods127.  
Another study links the cerebellar cortex and subthalamic nucleus128.  This work utilizing tract 
tracing methods provides evidence for substantial communication between the cerebellum and 
basal ganglia that is independent of the cerebral cortex128.  
This study shows robust occurrences of myoclonic responses two days following ACA, 
and other data (not shown) from our group shows that myoclonus persists at least twelve days 
following ACA.  Future research should utilize fluorojade staining to evaluate if cerebellar cell 
death correlates to occurrence of myoclonic responses, which may provide clues for the source of 
this phenotype after HIBI.  
Given the impact of ACA-induced HIBI on striatal MSNs as well as the larger associated 
basal ganglia circuitry, we evaluated the effects of chronic, systemic zolpidem administration on 
normalizing striatal DA neurotransmission and ameliorating HIBI-induced behavioral deficits.   
Maximal evoked DA were not significantly different between zolpidem-treated and 
untreated ACA animals.  However, ANOVA showed that zolpidem-treated (0.1mg/kg and 
0.2mg/kg) animals were not significantly different from Sham animals either, suggesting a very 
modest reduction in maximal evoked DA compared to the untreated ACA group.  Further, daily 
zolpidem had no apparent effect on DA release or DA reuptake kinetics, with outcomes remaining 
significantly different from sham animals for total DA released, initial DA release rate, and Vmax.  
With regard to reflexive behavior, the higher zolpidem dose (0.2mg/kg) normalized ASR outcomes 
for the 95-dB and 105-dB sound bursts but had minimal effect on reducing occurrence of 
myoclonic responses 2 days post-injury.  High dose zolpidem also had mild beneficial reductions 
in anhedonia compared to untreated ACA animals.  Similar to myoclonic responses, neither the 
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pooled group of low-and high-dose zolpidem-treated animals nor the high dose zolpidem group 
on its own significantly improved exploration or mobility in the open field.   
Interestingly, the high dose zolpidem groups showed a dichotomy of outcome for both 
dosages, broken up into “responders” and non-responders”.  The lack of significant zolpidem 
effects on behavior and DA neurotransmission could be due to the small sample size, but the basal 
ganglia’s dispersed distribution of GABA-A receptors and dynamic changes in neuronal 
damage/dysfunction resulting from HIBI greatly complicate the effects of systemic zolpidem 
administration. GABAA α-1 receptors are the principal target of zolpidem.  the α-1 subunit is the 
most abundant GABAA subunit and is found with variable distribution throughout the brain 1,2.  
Within the structures of interest, GABAA α-1 receptors are found in low concentrations in the 
striatum and SN, high concentrations in the GP, and very high concentrations in various thalamic 
nuclei including the tRN91.  SNpr GABA-A receptors mediate nigral GABAergic output, but these 
receptors are also found on DAergic SNpc neurons where their activation causes DA neuron 
inhibition.  In fact, 70% or more of SNpc DAergic neuron afferents are GABAergic37, and are 
largely projected from the SNpr.   
Neither low- or high-dose zolpidem significantly reduced evoked DA.  Considering the 
spatial distribution of GABAA α-1 receptors throughout the basal ganglia, systemic zolpidem 
administration may selectively bind pallidal GABAA α-1 receptors, thus increasing pallidal output.  
Whereas inhibition of pallidal output on the part of zolpidem presumably leads to a decrease in the 
firing of DA neurons due to disinhibition of SNpr GABAergic neurons, an increase in pallidal 
output may lead to burst firing in DA neurons and a significant increase in extracellular striatal 
DA37, despite its expected inhibitory effects on dopaminergic neuron firing.  Nigral GABAergic 
neurons are more sensitive to GABAA-mediated inhibition than nigral dopaminergic neurons, in 
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part due to a more hyperpolarized GABA-A reversal potential37.  This effect is so robust that the 
systemic administration of the GABA-A agonist, muscimol, leads to an increase in spontaneous 
DA neuron firing rates130 and elicits an increase in striatal dopamine levels131,132.  Low-intensity 
electrical stimulation of these GABAergic afferents33 also prompts activation and asynchronous 
GABA release, preferentially inhibiting the more sensitive GABAergic neurons with only minimal 
direct effects on the dopaminergic neurons. This leads to a disinhibition of the dopaminergic 
neurons as the tonically active SNpr GABAergic neurons are silenced, resulting in an increase in 
burst firing and a consequent increase in striatal dopamine levels despite only a minimal increase 
in their firing rate35. Although all of these manipulations likely add some direct inhibition of nigral 
dopaminergic neurons, they remove a far greater amount by inhibiting the tonically active SNpr 
GABAergic neurons.  Given the dichotomy in behavioral outcomes observed with the high dose 
zolpidem group, higher zolpidem concentrations may mediate this SNpc disinhibition that 
exacerbates striatal hyperdopaminergia.  Future work should assess DA neurotransmission in ACA 
animals given higher doses of zolpidem in order to elucidate the effects of higher zolpidem 
concentrations on striatal DA levels.  
Regional differences within the dorsal striatum relative to electrode placement during 
FSCV studies may have also impacted varied DA responses.   The dorsal striatum is also a 
functionally heterogeneous region, with microstructure differences in the grey and white matter 
(a.k.a. striata) as well as neurochemically distinct striosome and matrix compartments, and these 
distinct compartments exhibit differing DA release properties133,134.  Though our FSCV studies 
employed consistent coordinates for carbon fiber electrode placement, heterogeneity from animal 
to animal may have led to variations of electrode placement relative to different striatal 
compartments, thus affecting FSCV data readouts.  Future work should also contextualize this 
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heterogeneity in DA neurotransmission relative to ACA to further characterize HIBI-induced DA 
neurotransmission deficits in the D-STR. 
The opposing action of DA and ACh also plays an important role in basal ganglia 
physiology. MSN output is modulated by striatal aspiny cholinergic interneurons and DAergic 
stimulation of MSNs is modulated by cholinergic input from aspiny neurons and from 
glutamatergic cortico-striatal afferents. These are tonically active, pacemaker neurons that in turn 
receive inhibitory dopaminergic projections from the SNpc86,135, forming a dynamic equilibrium 
which, when disrupted, drives severe behavioral deficits136,137 and movement disorders resembling 
those associated with PD and HD. PD patients experience a pathologic gain of aspiny Ach output, 
perhaps consequently from reduced nigrostriatal dopaminergic tone135,138, whereas HD is 
characterized by a relative loss in striatal Ach signaling that may contribute to movement 
disorders86,138.  The relative overabundance of striatal DA seen after HIBI likely causes tonic 
inhibition of striatal cholinergic interneurons which, combined with the loss of aspiny ACh output 
due to MSN damage after HIBI, drive motor abnormalities and DoC that impair function after CA.  
Aspiny ACh interneurons exert their effect by acting on MSN muscarinic receptors.  M4 activation 
on D1 MSNs blunt MSN output while M1 activation on both D1 and D2 MSNs provides an 
excitatory effect86,139.  M5 receptors also regulate DA release by mediating its release in the SNpc 
whereas they inhibit DA release from terminals in the striatum140.   
Donepezil, an acetylcholinesterase inhibitor widely used in Alzheimer’s and dementia 
spectrum disorders, has the potential to modulate cholinergic and dopaminergic pathways in the 
basal ganglia, suggesting promise for its use to modulate post-HIBI movement disorders.  Recent 
studies in mice have demonstrated improved hyper-dopaminergic striatal function with 
administration of donepezil, effectively elevating acetylcholine levels in the striatum and 
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counteracting dopaminergic-driven inhibition87.  Recent clinical case studies report improved 
arousal and ameliorated motor impairments with a combined administration of donepezil and 
zolpidem63.  The addition of cholinergic modulation (via donepezil) combined with zolpidem may 
synergistically counter striatal aspiny ACh interneuron inhibition that drives DA signaling 
disruptions and motor disorders, as well as normalize thalamocortical signaling to rectify DoC 
post-HIBI. This dual therapy approach may help each individual treatment work more effectively 
while also limiting their potentially deleterious effects on this ACA-relevant circuitry.  Donepezil 
administration may help reverse striatal hyperdopaminergia by normalizing general MSN firing 
and the D1 MSN vs. D2 MSN firing mismatch associated with the D2 MSN selective vulnerability 
to HIBI.  Increasing D2 MSN firing will in turn reduce GPe output, which indirectly drives 
inhibition onto SNpc DAergic neurons.  Further, because over-activation of D1 MSNs elevates 
thalamocortical signaling, donepezil may help to ameliorate post-HIBI DoC by reducing D1 MSN 
firing.   
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Figure 22: Effects of HIBI on basal ganglia circuitry before (A) and after (B) systemic donepezil administration. 
(A) HIBI causes damage/dysfunction to striatal MSNs, particularly those expressing D2Rs.  This
mismatch is aggravated by striatal hyperdopaminergia, which chronically inhibits aspiny ACh
interneurons, thus over-activating D1 MSNs and over-inhibiting D2 MSNs 
(B) Donepezil may reverse striatal hyperdopaminergia by reducing D1 MSN firing and increasing D2
MSN firing through increased cholinergic effects on M4 and M1 muscarinic receptors, respectively. 
Donepezil may reduce DA levels in the setting of hyperdopaminergia directly by M5 effects at DA
terminals to decrease DA release. 
Though HIBI results in amplified GPi inhibitory drive which would presumably suppress 
thalamocortical signaling, animal models show elevated thalamocortical neuronal firing after 
CA70,71.The dense population of thalamic GABAA- α-1 receptors suggests systemic zolpidem may 
dominantly exert its effects in the thalamus, helping to normalize thalamocortical signaling as well.  
Combined with the increased D2 MSN firing due to donepezil treatment, zolpidem may also help 
to reverse striatal hyperdopaminergia by reducing GPe outflow, indirectly driving inhibition onto 
SNpc DAergic neurons. 
Zolpidem’s use as a clinical tool to promote arousal and ameliorate motor impairments in 
the chronic post-cardiac arrest phase has very mixed results66–68,73–76,141.  For individuals who 
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respond positively to zolpidem in clinical settings, the benefit varies greatly but is generally 
characterized by short-term improvements in arousal closely associated with the timing of its 
administration66,74,76.  The present study employed lower dosages of zolpidem (0.1-0.2mg/kg) and 
an administration timepoint relative to subsequent behavioral assessments (20 minutes prior) based 
on previous animal work, which optimized zolpidem dosages for improving motor deficits in a 6-
OHDA lesion study, a common Parkinson’s disease model.  Future work should further titrate 
zolpidem administration dosages and timepoints that most effectively combat post-HIBI 
neurological sequelae.  
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6.0 Conclusion 
This study evaluated the utility of neurological assessments and physiological readouts, in 
the acute post-ACA phase, for predicting survival probability as well as long-term behavioral and 
DA neurotransmission outcomes.  The Cox regression model ran suggests promise for NDS as a 
useful prognostic tool.  Additionally, the partial correlation analyses employed revealed robust 
correlations between DA release-based metrics and reflexive and cognitive behavioral outcomes.  
Our zolpidem pilot study showed mixed effects in its systemic administration improving 
behavioral impairments and reversing striatal hyperdopaminergia, though the higher dosage 
evaluated reversed the amplified startle response seen after CA as well as post-CA anhedonia, as 
defined by ASR and sucrose preference testing, respectively.  
Future research should continue exploring the utility of different neurological assessments 
and acute physiological readouts in predicting long-term survival or behavioral outcomes after 
ACA.  Zolpidem’s effects at various dosages and various administration timepoints relative to 
behavioral assessments, as well as the empirical effects of zolpidem microinjections in different 
basal ganglia regions should also be explored in addition to the effects of combined cholinergic 
and GABAergic manipulations with donepezil and zolpidem, respectively.  With regard to FSCV, 
future work should also further characterize heterogeneity of DA neurotransmission properties 
among different strisomes and striatal matrix compartments by systematically changing 
measurement coordinates combined with voltammetric and/or electrophysiological recordings.  
The electrode placements can be histologically verified by identifying capillary tube damage in 
the striatum and where it is seen relative to the internal capsule or other anatomical landmarks.  
Additionally, CA research should continue working to unravel the mechanisms underlying HIBI-
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induced behavioral impairments with western blotting to evaluate protein expression changes after 
CA, as well as immunostaining techniques to characterize dynamic changes of 
microglial/astrocytic activation and inflammatory marker expression that may mediate aberrant 
DA signaling and post-CA functional impairments.  Lastly, the dynamic changes in bioenergetics 
after CA and how these changes affect neuronal dysfunction in the larger striatal-pallidal-thalamic 
circuitry should be explored, such as dynamic changes in cerebral blood flow over time – these 
insights may help to explain dynamic changes in DA neurotransmission or behavioral 
abnormalities observed at various timepoints following CA.   
 
 66 
Bibliography 
1.  Mozaffarian D, Benjamin EJ, Go AS, et al. Heart Disease and Stroke Statistics—2016 
Update. Circulation. Published online January 1, 2015:CIR.0000000000000350. 
doi:10.1161/CIR.0000000000000350 
2.  Multi-Society Task Force on PVS. Medical aspects of the persistent vegetative state (1). N 
Engl J Med. 1994;330(21):1499-1508. doi:10.1056/NEJM199405263302107 
3.  Howell K, Grill E, Klein A-M, Straube A, Bender A. Rehabilitation outcome of anoxic-
ischaemic encephalopathy survivors with prolonged disorders of consciousness. 
Resuscitation. 2013;84(10):1409-1415. doi:10.1016/j.resuscitation.2013.05.015 
4.  Lu-Emerson C, Khot S. Neurological sequelae of hypoxic-ischemic brain injury. 
NeuroRehabilitation. 2010;26(1):35-45. doi:10.3233/NRE-2010-0534 
5.  Bales JW, Wagner AK, Kline AE, Dixon CE. Persistent cognitive dysfunction after 
traumatic brain injury: A dopamine hypothesis. Neurosci Biobehav Rev. 2009;33(7):981-
1003. doi:10.1016/j.neubiorev.2009.03.011 
6.  Nora GJ, Harun R, Fine DF, et al. Ventricular fibrillation cardiac arrest produces a chronic 
striatal hyperdopaminergic state that is worsened by methylphenidate treatment. J 
Neurochem. 2017;142(2):305-322. doi:10.1111/jnc.14058 
7.  Drabek T, Foley LM, Janata A, et al. Global and regional differences in cerebral blood flow 
after asphyxial versus ventricular fibrillation cardiac arrest in rats using ASL-MRI. 
Resuscitation. 2014;85(7):964-971. doi:10.1016/j.resuscitation.2014.03.314 
8.  Tsai M-S, Huang C-H, Tsai S-H, et al. The difference in myocardial injuries and 
mitochondrial damages between asphyxial and ventricular fibrillation cardiac arrests. Am J 
Emerg Med. 2012;30(8):1540-1548. doi:10.1016/j.ajem.2012.01.001 
9.  Laptook AR, Corbett RJT. The effects of temperature on hypoxic-ischemic brain injury. 
Clin Perinatol. 2002;29(4):623-649, vi. doi:10.1016/s0095-5108(02)00057-x 
10.  Chu Stacy Y., Cox Margueritte, Fonarow Gregg C., et al. Temperature and Precipitation 
Associate With Ischemic Stroke Outcomes in the United States. Journal of the American 
Heart Association. 2018;7(22):e010020. doi:10.1161/JAHA.118.010020 
11.  Nikolova S, Lee T-Y, Bartha R. The Severity of Ischemia Varies in Sprague-Dawley Rats 
from Different Vendors. ISRN Stroke. doi:https://doi.org/10.1155/2014/919652 
 67 
12.  Jia X, Koenig MA, Nickl R, Zhen G, Thakor NV, Geocadin RG. Early electrophysiologic 
markers predict functional outcome associated with temperature manipulation after cardiac 
arrest in rats. Crit Care Med. 2008;36(6):1909-1916. doi:10.1097/CCM.0b013e3181760eb5 
13.  Neumar RW, Bircher NG, Sim KM, et al. Epinephrine and sodium bicarbonate during CPR 
following asphyxial cardiac arrest in rats. Resuscitation. 1995;29(3):249-263. 
doi:10.1016/0300-9572(94)00827-3 
14.  von Auenmueller KI, Christ M, Sasko BM, Trappe H-J. The Value of Arterial Blood Gas 
Parameters for Prediction of Mortality in Survivors of Out-of-hospital Cardiac Arrest. J 
Emerg Trauma Shock. 2017;10(3):134-139. doi:10.4103/JETS.JETS_146_16 
15.  Björklund E, Lindberg E, Rundgren M, Cronberg T, Friberg H, Englund E. Ischaemic brain 
damage after cardiac arrest and induced hypothermia--a systematic description of selective 
eosinophilic neuronal death. A neuropathologic study of 23 patients. Resuscitation. 
2014;85(4):527-532. doi:10.1016/j.resuscitation.2013.11.022 
16.  Brisson CD, Hsieh Y-T, Kim D, Jin AY, Andrew RD. Brainstem neurons survive the 
identical ischemic stress that kills higher neurons: insight to the persistent vegetative state. 
PLoS ONE. 2014;9(5):e96585. doi:10.1371/journal.pone.0096585 
17.  Galvin KA, Oorschot DE. Continuous low-dose treatment with brain-derived neurotrophic 
factor or neurotrophin-3 protects striatal medium spiny neurons from mild neonatal 
hypoxia/ischemia: a stereological study. Neuroscience. 2003;118(4):1023-1032. 
18.  Wu X, Drabek T, Kochanek PM, et al. Induction of profound hypothermia for emergency 
preservation and resuscitation allows intact survival after cardiac arrest resulting from 
prolonged lethal hemorrhage and trauma in dogs. Circulation. 2006;113(16):1974-1982. 
doi:10.1161/CIRCULATIONAHA.105.587204 
19.  Pulsinelli WA, Brierley JB, Plum F. Temporal profile of neuronal damage in a model of 
transient forebrain ischemia. Ann Neurol. 1982;11(5):491-498. doi:10.1002/ana.410110509 
20.  Charvin D, Vanhoutte P, Pages C, Borrelli E, Caboche J. Unraveling a role for dopamine in 
Huntington’s disease: The dual role of reactive oxygen species and D2 receptor stimulation. 
2005;102(34):12218-12223. doi:10.1073/pnas.0502698102 
21.  Van Oostrom JCH, Maguire RP, Verschuuren-Bemelmans CC, et al. Striatal dopamine D2 
receptors, metabolism, and volume in preclinical Huntington disease. 2005;65(6):941-943. 
doi:10.1212/01.wnl.0000176071.08694.cc 
22.  Dale RC, Merheb V, Pillai S, et al. Antibodies to surface dopamine-2 receptor in 
autoimmune movement and psychiatric disorders. Brain. 2012;135(Pt 11):3453-3468. 
doi:10.1093/brain/aws256 
23.  Groman SM, Jentsch JD. Cognitive control and the dopamine D2-like receptor: a 
dimensional understanding of addiction. 2012;29(4):295-306. doi:10.1002/da.20897 
 68 
24.  Karimi M, Perlmutter JS. The role of dopamine and dopaminergic pathways in dystonia: 
insights from neuroimaging. Tremor Other Hyperkinet Mov (N Y). 2015;5:280. 
doi:10.7916/D8J101XV 
25.  Reiner A, Albin RL, Anderson KD, D’Amato CJ, Penney JB, Young AB. Differential loss 
of striatal projection neurons in Huntington disease. 1988;85(15):5733-5737. 
doi:10.1073/pnas.85.15.5733 
26.  Deng YP, Albin RL, Penney JB, Young AB, Anderson KD, Reiner A. Differential loss of 
striatal projection systems in Huntington’s disease: a quantitative immunohistochemical 
study. 2004;27(3):143-164. doi:10.1016/j.jchemneu.2004.02.005 
27.  Katayama Y, Kawamata T, Tamura T, Hovda DA, Becker DP, Tsubokawa T. Calcium-
dependent glutamate release concomitant with massive potassium flux during cerebral 
ischemia in vivo. Brain Res. 1991;558(1):136-140. 
28.  Kondoh T, Korosue K, Lee SH, Heros RC, Low WC. Evaluation of monoaminergic 
neurotransmitters in the rat striatum during varied global cerebral ischemia. Neurosurgery. 
1994;35(2):278-285; discussion 285-286. 
29.  Bird ED. Chemical pathology of Huntington’s disease. Annu Rev Pharmacol Toxicol. 
1980;20:533-551. doi:10.1146/annurev.pa.20.040180.002533 
30.  Cronberg T, Lilja G, Rundgren M, Friberg H, Widner H. Long-term neurological outcome 
after cardiac arrest and therapeutic hypothermia. Resuscitation. 2009;80(10):1119-1123. 
doi:10.1016/j.resuscitation.2009.06.021 
31.  Andersson A-E, Rosén H, Sunnerhagen KS. Life after cardiac arrest: A very long term 
follow up. Resuscitation. 2015;91:99-103. doi:10.1016/j.resuscitation.2015.01.009 
32.  Tiainen M, Poutiainen E, Oksanen T, et al. Functional outcome, cognition and quality of 
life after out-of-hospital cardiac arrest and therapeutic hypothermia: data from a randomized 
controlled trial. Scand J Trauma Resusc Emerg Med. 2015;23:12. doi:10.1186/s13049-014-
0084-9 
33.  Grace AA, Bunney BS. Opposing effects of striatonigral feedback pathways on midbrain 
dopamine cell activity. Brain Res. 1985;333(2):271-284. 
34.  Celada P, Paladini CA, Tepper JM. GABAergic control of rat substantia nigra dopaminergic 
neurons: role of globus pallidus and substantia nigra pars reticulata. Neuroscience. 
1999;89(3):813-825. 
35.  Lee CR, Abercrombie ED, Tepper JM. Pallidal control of substantia nigra dopaminergic 
neuron firing pattern and its relation to extracellular neostriatal dopamine levels. 
Neuroscience. 2004;129(2):481-489. doi:10.1016/j.neuroscience.2004.07.034 
 69 
36.  Smith Y, Bolam JP. The output neurones and the dopaminergic neurones of the substantia 
nigra receive a GABA-Containing input from the globus pallidus in the rat. Journal of 
Comparative Neurology. 1990;296(1):47-64. doi:10.1002/cne.902960105 
37.  Tepper JM, Lee CR. GABAergic control of substantia nigra dopaminergic neurons. Prog 
Brain Res. 2007;160:189-208. doi:10.1016/S0079-6123(06)60011-3 
38.  Robinson RG. Neuropsychiatric consequences of stroke. Annu Rev Med. 1997;48:217-229. 
doi:10.1146/annurev.med.48.1.217 
39.  Hachinski V. Post-stroke depression, not to be underestimated. Lancet. 
1999;353(9166):1728. doi:10.1016/S0140-6736(99)00139-7 
40.  Hajnal A, Norgren R. Taste pathways that mediate accumbens dopamine release by sapid 
sucrose. Physiol Behav. 2005;84(3):363-369. doi:10.1016/j.physbeh.2004.12.014 
41.  Hajnal A, Smith GP, Norgren R. Oral sucrose stimulation increases accumbens dopamine 
in the rat. Am J Physiol Regul Integr Comp Physiol. 2004;286(1):R31-37. 
doi:10.1152/ajpregu.00282.2003 
42.  Berridge KC, Ho C-Y, Richard JM, DiFeliceantonio AG. The tempted brain eats: Pleasure 
and desire circuits in obesity and eating disorders. Brain Res. 2010;1350:43-64. 
doi:10.1016/j.brainres.2010.04.003 
43.  Felger JC, Miller AH. Cytokine effects on the basal ganglia and dopamine function: the 
subcortical source of inflammatory malaise. Front Neuroendocrinol. 2012;33(3):315-327. 
doi:10.1016/j.yfrne.2012.09.003 
44.  Felger JC, Treadway MT. Inflammation Effects on Motivation and Motor Activity: Role of 
Dopamine. Neuropsychopharmacology. 2017;42(1):216-241. doi:10.1038/npp.2016.143 
45.  Miller AH, Haroon E, Raison CL, Felger JC. Cytokine targets in the brain: impact on 
neurotransmitters and neurocircuits. Depress Anxiety. 2013;30(4):297-306. 
doi:10.1002/da.22084 
46.  Janata A, Magnet IAM, Uray T, et al. Regional TNFα mapping in the brain reveals the 
striatum as a neuroinflammatory target after ventricular fibrillation cardiac arrest in rats. 
Resuscitation. 2014;85(5):694-701. doi:10.1016/j.resuscitation.2014.01.033 
47.  Pang KCH, Sinha S, Avcu P, et al. Long-lasting suppression of acoustic startle response 
after mild traumatic brain injury. J Neurotrauma. 2015;32(11):801-810. 
doi:10.1089/neu.2014.3451 
48.  Braff DL, Light GA, Swerdlow NR. Prepulse inhibition and P50 suppression are both 
deficient but not correlated in schizophrenia patients. Biol Psychiatry. 2007;61(10):1204-
1207. doi:10.1016/j.biopsych.2006.08.015 
 70 
49.  Geyer MA, Braff DL. Startle habituation and sensorimotor gating in schizophrenia and 
related animal models. Schizophr Bull. 1987;13(4):643-668. doi:10.1093/schbul/13.4.643 
50.  Swerdlow NR, Paulsen J, Braff DL, Butters N, Geyer MA, Swenson MR. Impaired prepulse 
inhibition of acoustic and tactile startle response in patients with Huntington’s disease. J 
Neurol Neurosurg Psychiatry. 1995;58(2):192-200. 
51.  Carlson S, Willott JF. Caudal pontine reticular formation of C57BL/6J mice: responses to 
startle stimuli, inhibition by tones, and plasticity. J Neurophysiol. 1998;79(5):2603-2614. 
doi:10.1152/jn.1998.79.5.2603 
52.  Lingenhöhl K, Friauf E. Giant neurons in the rat reticular formation: a sensorimotor 
interface in the elementary acoustic startle circuit? J Neurosci. 1994;14(3 Pt 1):1176-1194. 
53.  Koch M, Schnitzler H-U. The acoustic startle response in rats—circuits mediating 
evocation, inhibition and potentiation. Behavioural Brain Research. 1997;89(1):35-49. 
doi:10.1016/S0166-4328(97)02296-1 
54.  Sridharan D, Prashanth PS, Chakravarthy VS. The role of the basal ganglia in exploration 
in a neural model based on reinforcement learning. Int J Neural Syst. 2006;16(2):111-124. 
doi:10.1142/S0129065706000548 
55.  O’Keefe J, Nadel L. The Hippocampus as a Cognitive Map. Clarendon Press ; Oxford 
University Press; 1978. 
56.  Winter B, Juckel G, Viktorov I, et al. Anxious and hyperactive phenotype following brief 
ischemic episodes in mice. Biol Psychiatry. 2005;57(10):1166-1175. 
doi:10.1016/j.biopsych.2005.02.010 
57.  Kilic E, Kilic U, Bacigaluppi M, et al. Delayed melatonin administration promotes neuronal 
survival, neurogenesis and motor recovery, and attenuates hyperactivity and anxiety after 
mild focal cerebral ischemia in mice. J Pineal Res. 2008;45(2):142-148. 
doi:10.1111/j.1600-079X.2008.00568.x 
58.  Milot M, Plamondon H. Ischemia-induced hyperactivity: effects of dim versus bright 
illumination on open-field exploration and habituation following global ischemia in rats. 
Behav Brain Res. 2008;192(2):166-172. doi:10.1016/j.bbr.2008.03.044 
59.  Milot MR, Plamondon H. Time-dependent effects of global cerebral ischemia on anxiety, 
locomotion, and habituation in rats. Behavioural Brain Research. 2009;200(1):173-180. 
doi:10.1016/j.bbr.2009.01.009 
60.  Clauss R, Nel W. Drug induced arousal from the permanent vegetative state. 
NeuroRehabilitation. 2006;21(1):23-28. 
61.  Clauss RP, Güldenpfennig WM, Nel HW, Sathekge MM, Venkannagari RR. Extraordinary 
arousal from semi-comatose state on zolpidem. A case report. S Afr Med J. 2000;90(1):68-
72. 
 71 
62.  Kim C, Kwon BS, Nam KY, Park JW, Lee HJ. Zolpidem-Induced Arousal by Paradoxical 
GABAergic Stimulation: A Case Report With F-18 Flumazenil Positron Emission 
Tomography and Single Photon Emission Computed Tomography Study. Ann Rehabil Med. 
2016;40(1):177-181. doi:10.5535/arm.2016.40.1.177 
63.  Davis WA., Linsenmeyer M., Wagner AK. Donepezil and Zolpidem Associated Emergence 
from Disordered Consciousness after Cardiac Arrest: Modulating cholinergic and GABA-
ergic Striato-pallidal-thalamic Circuitry. .  In Review, Neurocase. Published online 2019. 
64.  Pinto SM., Kandt JA., Ferimer S, Wagner AK. Donepezil and Zolpidem Associated 
Emergence from Disordered Consciousness after Cardiac Arrest:  Implications involving 
Striatal Circuitry and Dopamine Modulation. Am J PhysMed & Rehabil. 2017; 96(3): 
Supplement 1. A46. 
65.  Desmarais, LA., Milleville KB., Wagner AK. Zolpidem Treatment of Post-Operative 
Venous Congestion associated Brain Injury. In Review, AJPMR. Published online 2020. 
66.  Arruda WO, Silva MS, Bertholdo DB, Munhoz RP, Teive HAG. Zolpidem in movement 
disorders after cardiac arrest. Parkinsonism & Related Disorders. 2017;37:114-115. 
doi:10.1016/j.parkreldis.2017.01.007 
67.  Bomalaski MN, Claflin ES, Townsend W, Peterson MD. Zolpidem for the Treatment of 
Neurologic Disorders. JAMA Neurology. 2017;74(9):1130. 
doi:10.1001/jamaneurol.2017.1133 
68.  Schiff ND. Recovery of consciousness after brain injury: a mesocircuit hypothesis. Trends 
in Neurosciences. 2010;33(1):1-9. doi:10.1016/j.tins.2009.11.002 
69.  Goetz T, Arslan A, Wisden W, Wulff P. GABA(A) receptors: structure and function in the 
basal ganglia. Prog Brain Res. 2007;160:21-41. doi:10.1016/S0079-6123(06)60003-4 
70.  Shoykhet M, Simons DJ, Alexander H, Hosler C, Kochanek PM, Clark RSB. 
Thalamocortical Dysfunction and Thalamic Injury after Asphyxial Cardiac Arrest in 
Developing Rats. J Neurosci. 2012;32(14):4972-4981. doi:10.1523/JNEUROSCI.5597-
11.2012 
71.  Aravamuthan BR, Shoykhet M. Long-term increase in coherence between the basal ganglia 
and motor cortex after asphyxial cardiac arrest and resuscitation in developing rats. Pediatr 
Res. 2015;78(4):371-379. doi:10.1038/pr.2015.114 
72.  Thibaut A, Schiff N, Giacino J, Laureys S, Gosseries O. Therapeutic interventions in 
patients with prolonged disorders of consciousness. The Lancet Neurology. 2019;18(6):600-
614. doi:10.1016/s1474-4422(19)30031-6 
73.  Brefel-Courbon C, Payoux P, Ory F, et al. Clinical and imaging evidence of zolpidem effect 
in hypoxic encephalopathy. Annals of Neurology. 2007;62(1):102-105. 
doi:10.1002/ana.21110 
 72 
74.  Thonnard M, Gosseries O, Demertzi A, et al. Effect of zolpidem in chronic disorders of 
consciousness: a prospective open-label study. Funct Neurol. Published online January 11, 
2014:1-6. 
75.  Whyte J, Myers R. Incidence of clinically significant responses to zolpidem among patients 
with disorders of consciousness: a preliminary placebo controlled trial. Am J Phys Med 
Rehabil. 2009;88(5):410-418. doi:10.1097/PHM.0b013e3181a0e3a0 
76.  Whyte J, Rajan R, Rosenbaum A, et al. Zolpidem and restoration of consciousness. Am J 
Phys Med Rehabil. 2014;93(2):101-113. doi:10.1097/PHM.0000000000000069 
77.  Carrillo P, Takasu A, Safar P, et al. Prolonged severe hemorrhagic shock and resuscitation 
in rats does not cause subtle brain damage. J Trauma. 1998;45(2):239-248; discussion 248-
249. 
78.  Katz L, Ebmeyer U, Safar P, Radovsky A, Neumar R. Outcome model of asphyxial cardiac 
arrest in rats. J Cereb Blood Flow Metab. 1995;15(6):1032-1039. 
doi:10.1038/jcbfm.1995.129 
79.  Janata A, Drabek T, Magnet IAM, et al. Extracorporeal versus conventional 
cardiopulmonary resuscitation after ventricular fibrillation cardiac arrest in rats: a feasibility 
trial. Crit Care Med. 2013;41(9):e211-222. doi:10.1097/CCM.0b013e318287f51e 
80.  Harun R, Hare KM, Brough ME, et al. Fast-scan cyclic voltammetry demonstrates that L-
DOPA produces dose-dependent regionally selective, bimodal effects on striatal dopamine 
kinetics in vivo. J Neurochem. Published online November 27, 2015. doi:10.1111/jnc.13444 
81.  Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. 6th ed. Elsevier; 2007. 
82.  Wightman RM, Zimmerman JB. Control of dopamine extracellular concentration in rat 
striatum by impulse flow and uptake. Brain research Brain research reviews. 
1990;15(2):135-144. 
83.  Lam Y-W, Sherman SM. Functional Organization of the Thalamic Input to the Thalamic 
Reticular Nucleus. J Neurosci. 2011;31(18):6791-6799. doi:10.1523/JNEUROSCI.3073-
10.2011 
84.  Yeo SS, Chang PH, Jang SH. The ascending reticular activating system from pontine 
reticular formation to the thalamus in the human brain. Front Hum Neurosci. 2013;7:416. 
doi:10.3389/fnhum.2013.00416 
85.  Bariselli S, Fobbs WC, Creed MC, Kravitz AV. A competitive model for striatal action 
selection. Brain Res. 2019;1713:70-79. doi:10.1016/j.brainres.2018.10.009 
86.  Tanimura A, Pancani T, Lim SAO, et al. Striatal cholinergic interneurons and Parkinson’s 
disease. Eur J Neurosci. 2018;47(10):1148-1158. doi:10.1111/ejn.13638 
 73 
87.  Nair AG, Castro LRV, El Khoury M, et al. The high efficacy of muscarinic M4 receptor in 
D1 medium spiny neurons reverses striatal hyperdopaminergia. Neuropharmacology. 
2019;146:74-83. doi:10.1016/j.neuropharm.2018.11.029 
88.  Calabresi P, Picconi B, Tozzi A, Ghiglieri V, Di Filippo M. Direct and indirect pathways of 
basal ganglia: a critical reappraisal. Nat Neurosci. 2014;17(8):1022-1030. 
doi:10.1038/nn.3743 
89.  Haber SN. Corticostriatal circuitry. Dialogues Clin Neurosci. 2016;18(1):7-21. 
90.  Schiff ND, Posner JB. Another “Awakenings.” 2007;62(1):5-7. doi:10.1002/ana.21158 
91.  Sieghart W, Sperk G. Subunit composition, distribution and function of GABA(A) receptor 
subtypes. Curr Top Med Chem. 2002;2(8):795-816. doi:10.2174/1568026023393507 
92.  Chen L, Savio Chan C, Yung W-H. Electrophysiological and behavioral effects of zolpidem 
in rat globus pallidus. Experimental Neurology. 2004;186(2):212-220. 
doi:10.1016/j.expneurol.2003.11.003 
93.  Chen L, Xie J-X, Fung K-S, Yung W-H. Zolpidem modulates GABA(A) receptor function 
in subthalamic nucleus. Neurosci Res. 2007;58(1):77-85. doi:10.1016/j.neures.2007.02.002 
94.  Benhamou L, Bronfeld M, Bar-Gad I, Cohen D. Globus Pallidus External Segment Neuron 
Classification in Freely Moving Rats: A Comparison to Primates. PLoS One. 2012;7(9). 
doi:10.1371/journal.pone.0045421 
95.  Hattori T, Fibiger HC, McGeer PL. Demonstration of a pallido-nigral projection innervating 
dopaminergic neurons. J Comp Neurol. 1975;162(4):487-504. doi:10.1002/cne.901620406 
96.  Chergui K, Charléty PJ, Akaoka H, et al. Tonic activation of NMDA receptors causes 
spontaneous burst discharge of rat midbrain dopamine neurons in vivo. Eur J Neurosci. 
1993;5(2):137-144. doi:10.1111/j.1460-9568.1993.tb00479.x 
97.  Chergui K, Akaoka H, Charléty PJ, Saunier CF, Buda M, Chouvet G. Subthalamic nucleus 
modulates burst firing of nigral dopamine neurones via NMDA receptors. Neuroreport. 
1994;5(10):1185-1188. doi:10.1097/00001756-199406020-00006 
98.  Connelly ST, Shepard PD. Competitive NMDA receptor antagonists differentially affect 
dopamine cell firing pattern. Synapse. 1997;25(3):234-242. doi:10.1002/(SICI)1098-
2396(199703)25:3<234::AID-SYN2>3.0.CO;2-C 
99.  Saji M, Cohen M, Blau AD, Wessel TC, Volpe BT. Transient forebrain ischemia induces 
delayed injury in the substantia nigra reticulata: degeneration of GABA neurons, 
compensatory expression of GAD mRNA. Brain Res. 1994;643(1-2):234-244. 
doi:10.1016/0006-8993(94)90030-2 
 74 
100.  van den Brule JMD, van der Hoeven JG, Hoedemaekers CWE. Cerebral Perfusion and 
Cerebral Autoregulation after Cardiac Arrest. Biomed Res Int. 2018;2018. 
doi:10.1155/2018/4143636 
101.  Iordanova B, Li L, Clark RSB, Manole MD. Alterations in Cerebral Blood Flow after 
Resuscitation from Cardiac Arrest. Front Pediatr. 2017;5:174. 
doi:10.3389/fped.2017.00174 
102.  Park H-P, Nimmagadda A, DeFazio RA, Busto R, Prado R, Ginsberg MD. Albumin therapy 
augments the effect of thrombolysis on local vascular dynamics in a rat model of arteriolar 
thrombosis: a two-photon laser-scanning microscopy study. Stroke. 2008;39(5):1556-1562. 
doi:10.1161/STROKEAHA.107.502195 
103.  Györffy BA, Kun J, Török G, et al. Local apoptotic-like mechanisms underlie complement-
mediated synaptic pruning. Proc Natl Acad Sci USA. 2018;115(24):6303-6308. 
doi:10.1073/pnas.1722613115 
104.  Calabresi P, Centonze D, Bernardi G. Cellular factors controlling neuronal vulnerability in 
the brain: a lesson from the striatum. Neurology. 2000;55(9):1249-1255. 
doi:10.1212/wnl.55.9.1249 
105.  Maletic V, Robinson M, Oakes T, Iyengar S, Ball SG, Russell J. Neurobiology of 
depression: an integrated view of key findings. Int J Clin Pract. 2007;61(12):2030-2040. 
doi:10.1111/j.1742-1241.2007.01602.x 
106.  Kapur S, John Mann J. Role of the dopaminergic system in depression. Biological 
Psychiatry. 1992;32(1):1-17. doi:10.1016/0006-3223(92)90137-O 
107.  Dranovsky A, Hen R. Hippocampal neurogenesis: regulation by stress and antidepressants. 
Biol Psychiatry. 2006;59(12):1136-1143. doi:10.1016/j.biopsych.2006.03.082 
108.  Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med. 
2001;7(5):541-547. doi:10.1038/87865 
109.  Ressler KJ, Nemeroff CB. Role of serotonergic and noradrenergic systems in the 
pathophysiology of depression and anxiety disorders. Depress Anxiety. 2000;12 Suppl 1:2-
19. doi:10.1002/1520-6394(2000)12:1+<2::AID-DA2>3.0.CO;2-4 
110.  Müller MB, Holsboer F. Mice with mutations in the HPA-system as models for symptoms 
of depression. Biol Psychiatry. 2006;59(12):1104-1115. 
doi:10.1016/j.biopsych.2006.02.008 
111.  Mayberg HS. Modulating dysfunctional limbic-cortical circuits in depression: towards 
development of brain-based algorithms for diagnosis and optimised treatment. Br Med Bull. 
2003;65:193-207. doi:10.1093/bmb/65.1.193 
112.  Bodien YG, Chatelle C, Edlow BL. Functional Networks in Disorders of Consciousness. 
Semin Neurol. 2017;37(5):485-502. doi:10.1055/s-0037-1607310 
 75 
113.  Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. 
Brain Behav Immun. 2007;21(2):153-160. doi:10.1016/j.bbi.2006.09.006 
114.  Brooks N, Campsie L, Symington C, Beattie A, McKinlay W. The five year outcome of 
severe blunt head injury: a relative’s view. J Neurol Neurosurg Psychiatry. 1986;49(7):764-
770. doi:10.1136/jnnp.49.7.764 
115.  Hibbard MR, Uysal S, Kepler K, Bogdany J, Silver J. Axis I psychopathology in individuals 
with traumatic brain injury. J Head Trauma Rehabil. 1998;13(4):24-39. 
doi:10.1097/00001199-199808000-00003 
116.  Felger JC, Hernandez CR, Miller AH. Levodopa reverses cytokine-induced reductions in 
striatal dopamine release. Int J Neuropsychopharmacol. 2015;18(4). 
doi:10.1093/ijnp/pyu084 
117.  Janata A, Drabek T, Magnet IAM, et al. Extracorporeal versus conventional 
cardiopulmonary resuscitation after ventricular fibrillation cardiac arrest in rats: a feasibility 
trial. Crit Care Med. 2013;41(9):e211-222. doi:10.1097/CCM.0b013e318287f51e 
118.  Lee Y, López DE, Meloni EG, Davis M. A Primary Acoustic Startle Pathway: Obligatory 
Role of Cochlear Root Neurons and the Nucleus Reticularis Pontis Caudalis. J Neurosci. 
1996;16(11):3775-3789. doi:10.1523/JNEUROSCI.16-11-03775.1996 
119.  Hormigo S, López DE, Cardoso A, Zapata G, Sepúlveda J, Castellano O. Direct and indirect 
nigrofugal projections to the nucleus reticularis pontis caudalis mediate in the motor 
execution of the acoustic startle reflex. Brain Struct Funct. 2018;223(6):2733-2751. 
doi:10.1007/s00429-018-1654-9 
120.  Freund B, Kaplan PW. Myoclonus After Cardiac Arrest: Where Do We Go From Here? 
Epilepsy Curr. 2017;17(5):265-272. doi:10.5698/1535-7597.17.5.265 
121.  Elmer J, Torres C, Aufderheide TP, et al. Association of early withdrawal of life-sustaining 
therapy for perceived neurological prognosis with mortality after cardiac arrest. 
Resuscitation. 2016;102:127-135. doi:10.1016/j.resuscitation.2016.01.016 
122.  Wijdicks EF, Parisi JE, Sharbrough FW. Prognostic value of myoclonus status in comatose 
survivors of cardiac arrest. Ann Neurol. 1994;35(2):239-243. doi:10.1002/ana.410350219 
123.  Kanthasamy AG, Yun RJ, Nguyen B, Truong DD. Effect of riluzole on the neurological and 
neuropathological changes in an animal model of cardiac arrest-induced movement 
disorder. J Pharmacol Exp Ther. 1999;288(3):1340-1348. 
124.  Kanthasamy AG, Nguyen BQ, Truong DD. Animal model of posthypoxic myoclonus: II. 
Neurochemical, pathologic, and pharmacologic characterization. Movement Disorders. 
2000;15(S1):31-38. doi:10.1002/mds.870150707 
125.  Winblad B. Piracetam: A Review of Pharmacological Properties and Clinical Uses. CNS 
Drug Rev. 2005;11(2):169-182. doi:10.1111/j.1527-3458.2005.tb00268.x 
 76 
126.  Doya K. Complementary roles of basal ganglia and cerebellum in learning and motor 
control. Curr Opin Neurobiol. 2000;10(6):732-739. doi:10.1016/s0959-4388(00)00153-7 
127.  Hoshi E, Tremblay L, Féger J, Carras PL, Strick PL. The cerebellum communicates with 
the basal ganglia. Nat Neurosci. 2005;8(11):1491-1493. doi:10.1038/nn1544 
128.  Bostan AC, Strick PL. The Cerebellum and Basal Ganglia are Interconnected. Neuropsychol 
Rev. 2010;20(3):261-270. doi:10.1007/s11065-010-9143-9 
129.  Sieghart W, Sperk G. Subunit composition, distribution and function of GABA(A) receptor 
subtypes. Curr Top Med Chem. 2002;2(8):795-816. doi:10.2174/1568026023393507 
130.  Grace AA, Bunney BS. Paradoxical GABA excitation of nigral dopaminergic cells: indirect 
mediation through reticulata inhibitory neurons. Eur J Pharmacol. 1979;59(3-4):211-218. 
doi:10.1016/0014-2999(79)90283-8 
131.  Martin GE, Haubrich DR. Striatal dopamine release and contraversive rotation elicited by 
intranigrally applied muscimol. Nature. 1978;275(5677):230-231. doi:10.1038/275230a0 
132.  Santiago M, Westerink BH. The role of GABA receptors in the control of nigrostriatal 
dopaminergic neurons: dual-probe microdialysis study in awake rats. Eur J Pharmacol. 
1992;219(2):175-181. doi:10.1016/0014-2999(92)90294-e 
133.  Martin LJ. The Striatal Mosaic in Primates: Striosomes and Matrix Are Differentially 
Enriched in lonotropic Glutamate Receptor Subunits. :11. 
134.  Salinas AG, Davis MI, Lovinger DM, Mateo Y. Dopamine dynamics and cocaine sensitivity 
differ between striosome and matrix compartments of the striatum. Neuropharmacology. 
2016;108:275-283. doi:10.1016/j.neuropharm.2016.03.049 
135.  Ztaou S, Amalric M. Contribution of cholinergic interneurons to striatal pathophysiology in 
Parkinson’s disease. Neurochemistry International. 2019;126:1-10. 
doi:10.1016/j.neuint.2019.02.019 
136.  Jeon J, Dencker D, Wörtwein G, et al. A Subpopulation of Neuronal M4 Muscarinic 
Acetylcholine Receptors Plays a Critical Role in Modulating Dopamine-Dependent 
Behaviors. J Neurosci. 2010;30(6):2396-2405. doi:10.1523/JNEUROSCI.3843-09.2010 
137.  Aoki S, Liu AW, Zucca A, Zucca S, Wickens JR. Role of Striatal Cholinergic Interneurons 
in Set-Shifting in the Rat. J Neurosci. 2015;35(25):9424-9431. 
doi:10.1523/JNEUROSCI.0490-15.2015 
138.  Pisani A, Bernardi G, Ding J, Surmeier DJ. Re-emergence of striatal cholinergic 
interneurons in movement disorders. Trends in Neurosciences. 2007;30(10):545-553. 
doi:10.1016/j.tins.2007.07.008 
139.  Kuroiwa M, Hamada M, Hieda E, et al. Muscarinic receptors acting at pre- and post-synaptic 
sites differentially regulate dopamine/DARPP-32 signaling in striatonigral and 
 77 
striatopallidal neurons. Neuropharmacology. 2012;63(7):1248-1257. 
doi:10.1016/j.neuropharm.2012.07.046 
140.  Foster DJ, Gentry PR, Lizardi-Ortiz JE, et al. M5 receptor activation produces opposing 
physiological outcomes in dopamine neurons depending on the receptor’s location. J 
Neurosci. 2014;34(9):3253-3262. doi:10.1523/JNEUROSCI.4896-13.2014 
141.  Thibault D, Albert PR, Pineyro G, Trudeau L-É. Neurotensin triggers dopamine D2 receptor 
desensitization through a protein kinase C and beta-arrestin1-dependent mechanism. J Biol 
Chem. 2011;286(11):9174-9184. doi:10.1074/jbc.M110.166454 
 
